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ABSTRACT 
 In this dissertation, the roles of endocytosis and phagocytosis pathways in a 
variety of clinically relevant scenarios were examined.  These scenarios include 
antibody-mediated internalization of cell surface proteins, titanium wear-particle uptake 
in failed joint replacements, and polymeric microparticle uptake and immune responses 
for drug delivery or adjuvant use. 
 The use of antibodies specific for cell surface proteins has become a popular 
method to deliver therapeutics to target cells.  As such, it is imperative to fully 
understand the ability of antibodies to mediate internalization and endosomal trafficking 
of the surface protein that it recognizes, so that drug delivery can be optimized.  By 
comparing the internalization and endosomal localization of two different antibody-
bound proteins, the transferrin receptor (TfR) and rabies G, we have found that there is 
a specific antibody-mediated internalization pathway that occurs when an antibody 
binds to a cell surface protein.  Interestingly, the internalization pathway induced by 
antibody binding is different than that seen with recycling receptor internalization after 
ligand binding.  This may have broad implications for the future development of 
antibody-based therapeutics. 
 Joint replacement failure is a major clinical problem.  Studies have indicated 
that a large amount of metal and polyethylene wear debris is found in the synovial 
membrane and tissue surrounding failed replacements.  Through examination of the 
immune response following uptake of titanium particles, our results suggest that 
titanium wear-particle induced inflammation and subsequent joint replacement failure 
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may be due to activation of the NLRP3 inflammasome, leading to increased IL-1β 
secretion and IL-1 associated signaling.  These findings introduce IL-1 as a target for 
potential therapeutics for patients exhibiting significant inflammation. 
 Polymeric microparticles have been widely used in a variety of therapeutic 
applications, including drug delivery and vaccine adjuvants.  It is essential to 
understand the ability of such particles to either activate or inhibit an immune response 
following uptake.  Through comparison of particles with varying surface morphology, 
we have determined that particles with regions of high surface curvature (budding) are 
more immunogenic than particles with low surface curvature (spherical).  Budding 
particles were more rapidly phagocytosed and induced higher levels of the 
inflammasome-associated cytokine, IL-1β, when exposed to mouse macrophages.  
Additionally, budding particles induced a more rapid neutrophil response in vivo, when 
compared to spherical particles.  These findings have broad implications for the 
development of future targeting vehicles for delivery of vaccines, drugs, proteins, and 
siRNA therapeutics. 
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CHAPTER I 
Introduction 
 
Internalization of exogenous and cell-associated products is a highly regulated 
process that is involved in a number of functions that are essential for the cell, including 
receptor recycling and signaling, cell homeostasis, antigen presentation, and protection 
from extracellular pathogens.  The ability of cells to internalize ligand- or antibody-
bound cell surface receptors and to phagocytose foreign pathogens or particles has 
broad therapeutic implications for the treatment of a variety of diseases and disorders.  
In order to generate effective treatments, it is essential to fully understand the 
mechanisms involved in the various internalization pathways and, in the case of 
phagocytosis, the subsequent immune response. 
 
A.  INTERNALIZATION PATHWAYS 
There are several internalization pathways that cells utilize to perform the 
important functions listed above.  A brief description of what is known for each of these 
pathways is outlined below. 
Cellular internalization pathways include pinocytosis, phagocytosis, clathrin-
independent internalization, and clathrin-dependent receptor-mediated internalization.  
Pinocytosis, or cell drinking, refers to the internalization of small particles (i.e., those 
less than 200 nm in size) and is a way for cells to ingest fluids.  Phagocytosis, or cell 
eating, refers to internalization of large particles (i.e., those greater than 200 nm in size) 
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and is a way for immune cells to ingest foreign pathogens, dead or dying cells, and 
other particulate debris (1).  Clathrin-independent internalization refers to a variety of 
endocytosis mechanisms including caveolae-mediated, RhoA-mediated, CDC42-
medited, and ARF6-mediated pathways (2) for proteins like cholera toxin subunit B (3, 
4) and GPI-anchored proteins (4, 5).  Most receptor-mediated endocytosis processes in 
the cell, however, involve associations with clathrin and clathrin-mediated 
internalization.  Receptor-mediated internalization, also referred to as clathrin-mediated 
internalization, involves the binding of a protein to a particular receptor on the surface 
of the cell, like transferrin (Tf) and the transferrin receptor (TfR), resulting in cellular 
signaling, recruitment of clathrin and adaptor proteins and internalization of the cargo 
into the cell.  Both phagocytosis and receptor-mediated internalization pathways 
involve the cooperation of a variety of cellular processes in order to function properly.  
 
Phagocytosis Pathways 
 Phagocytosis is generally a receptor-mediated, actin-dependent, and clathrin-
independent mechanism of entry into cells for large cargo (>200 nm) (6, 7).  In 
mammals, phagocytosis is carried out by a specialized subset of cells termed 
‘professional phagocytes’, including neutrophils, monocytes, macrophages, and 
dendritic cells (8).  Phagocytosis serves as a defense against microorganisms, via 
pathogen-specific receptors or by opsonin-mediated (complement or antibody) binding.  
Phagocytosis also serves as a means to remove cellular and non-cellular particulate 
material from the extracellular space. 
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 Phagocytosis begins with recognition of the foreign, or dangerous, particle by a 
phagocyte.  Association of particles with the surface of phagocytic cells induces actin 
polymerization at the site of binding to assist in internalization (6-8).  Internalized 
vesicles containing phagocytosed material, termed phagosomes, through association 
with adaptor proteins involved in the endocytosis pathway, eventually fuse with 
lysosomes to form phagolysosomes, which contain acidic lysosomal components, 
including cathepsins (8-10).  Phagocytosis can occur through association with one of 
several different cell surface proteins, including complement receptors, Fc-receptors 
(FcR), scavenger receptors, and pathogen-specific receptors, like Toll-like receptors 
(TLRs), mannose receptors, and lectins (7, 11). 
 Complement-mediated phagocytosis can occur via one of the three major 
complement pathways in cells: the alternative pathway, the classical pathway, and the 
mannose binding lectin pathway.  The details of each pathway have been well 
characterized and have been reviewed extensively (12).  The major opsonins, or 
proteins involved in pathogen binding and recognition by macrophages, generated from 
these pathways include C3b, C3bi, and C4b.  Several complement receptors (CR) 
participate in the phagocytosis of complement-opsonized particles, including CR1, 
CR3, and CR4.  CR1 binds C3b, C4b, and C3bi, and is associated with particle binding 
(7).  CR3 and CR4 are integrin family members that bind C3bi and are associated with 
particle internalization (7).  Complement-mediated phagocytosis requires a secondary 
stimulus, such as cytokines or chemokines, in order to occur.  Additionally, uptake via 
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complement does not lead to the release of certain inflammatory mediators, including 
reactive oxygen species (ROS) (7). 
 FcRs that are involved in phagocytosis include FcγRI, FcγRIIA (in humans), and 
FcγRIII (13).  Binding of the Fc region of antibodies to the FcR results in receptor 
cross-linking and subsequent tyrosine phosphorylation of immune receptor tyrosine 
activation motifs (ITAMs) on the receptor itself (FcγRIIA) or on common γ subunits 
(FcγRI and FcγRIII (7) via src-family kinases (14).  This activation leads to the 
recruitment and activation of Syk kinases, which are responsible for cytoskeletal 
rearrangement, actin assembly, and downstream transcriptional activation of 
inflammatory cytokines (15, 16), via participation of PI-3 kinases, rho-GTPases, protein 
kinase C, and motor proteins (reviewed in (7)). 
 There are two major scavenger receptors involved in phagocytosis, Scavenger 
receptor A (SR-A) and macrophage receptor with collagenous structure (MARCO).  
SR-A, which is expressed in most macrophage populations (17-19), binds to whole 
microbes, recognizing LPS and lipoteichoic acids (20) while MARCO, expressed on 
certain subsets of macrophages (17, 18), recognizes a variety of Gram-positive and 
Gram-negative bacteria (21) as well as artificial latex and TiO2 (18), silica (22), and 
polystyrene particles (23). 
 Binding to TLRs and other pathogen/pattern recognition receptors like mannose 
receptors or lectins on the surface of immune cells represents another mechanism for 
phagocytosis.  Each receptor recognizes a particular moiety on the surface of pathogens, 
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and once bound, induces intracellular signaling pathways, including internalization and 
the release of pro-inflammatory cytokines including IL-6, TNF, and IL-1β. 
  
Clathrin-dependent receptor-mediated internalization 
 Receptor-mediated internalization, also commonly referred to as clathrin-
mediated internalization, involves the binding of a ligand to a receptor expressed on the 
surface of cells.  Clathrin-mediated internalization is most commonly associated with 
endocytosis of cell surface receptors and cell surface proteins.  The functional subunit 
of clathrin is the triskelion, formed from the interactions of three clathrin heavy chains 
and three light chains that create a three-legged polymer structure (24).  These 
triskelions then associate with each other through interactions between antiparallel 
proximal domains to create a hexagonal lattice coating on budding vesicles (25).   
 The internalization process starts with the formation of a structure known as a 
coated pit.  Formation of the coated pit is thought to begin with the recruitment of 
adaptor proteins, including AP-2, to a docking site on the plasma membrane.  Adaptor 
proteins then recruit clathrin, which self assembles into higher order triskelion 
structures to form a clathrin-coated pit (1, 26, 27).  With the help of several other 
adaptor and accessory proteins, including dynamin, the clathrin-coated pit moves away 
from the plasma membrane, until it eventually pinches off to form a clathrin-coated 
vesicle (CCV) (28).  Clathrin and most adaptor proteins are quickly shed from these 
vesicles and recycled back to the surface where they can participate in other pit 
formations (29, 30). 
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Role of actin in clathrin-mediated endocytosis 
 It has long been believed that actin plays a role in endocytosis, however it has 
been difficult to determine the specific requirement or function of actin in these 
pathways.  The role of actin in clathrin-mediated endocytosis is even more controversial 
since different groups have demonstrated that actin is both essential (31-34) and not 
essential (34-36).   
 Several groups have provided evidence arguing for a role of actin in receptor-
mediated internalization.  Lamaze et al. demonstrated that treatment of perforated or 
intact A431 cells with actin monomer sequestering drugs, like LA, inhibited receptor-
mediated endocytosis, including internalization of the TfR (31).  Yarar and colleagues 
have shown that actin dynamics are essential for a number of stages in clathrin-
mediated endocytosis, including coated-vesicle formation, invagination, and subsequent 
internalization (32).  Several recent reports have come out linking budding yeast 
proteins essential for endocytosis and actin nucleation to mammalian homologues that 
associate with clathrin adaptors (reviewed in (33)). 
 Other groups have provided evidence that actin is not essential for receptor-
mediated internalization.  Sandvig et al. have shown that drugs that inhibit actin 
polymerization, like cytochalasin D, have no effect on TfR internalization in 
mammalian cells, but do inhibit some fluid-phase endocytosis events (35). Treatment of 
polarized epithelial cells with cytochalasin D inhibited endocytosis from the apical 
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surface with no effect of endocytosis from the basolateral surface (36), including 
recycling of the TfR. 
 Although the role of actin in clathrin-mediated internalization remains unclear, 
its role in other internalization pathways including phagocytosis has been verified (6-8).  
The question of whether actin plays a dispensable or indispensable role in clathrin-
mediated internalization may depend on several variables, including the localization of 
membrane proteins on the plasma membrane, the type of cell, the ligand being studied, 
as well as the cellular growth conditions (34).  
 
B.  ENDOSOMAL COMPARTMENTS 
 As described above, once internalized within a cell, the CCV quickly uncoats 
and the subunits, namely clathrin and adaptor proteins, are recycled to participate in 
new rounds of internalization (29, 30).  Newly uncoated vesicles move along 
microtubules to fuse with other vesicles (37), and eventually move to early endosomes, 
where they are sorted into various compartments of the endosomal pathway based on 
cargo (Figure 1.1).  These compartments and their associated proteins exhibit specific 
functions for cargo sorting, delivery, and movement within the cell.  The major 
endocytic compartments and their functions are described in detail below. 
 There are four major classes of endosomal compartments in cells termed early 
endosomes (EE), late endosomes (LE), recycling endosomes (RE), and lysosomes.  The 
endosomal compartments are differentially characterized by their expression of proteins 
of the Rab family of small GTPases (Figure 1.1).  Lysosomes, on the other hand, are 
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Figure 1.1:  Endocytic compartments and associated proteins.  Cargo is internalized 
via clathrin into clathrin-coated vesicles (CCV).  CCV are delivered to early endosomes 
(EE) expressing Rab5 and Rab4.  Rapid recycling from EE to the plasma membrane is 
mediated by Rab4.  Slow recycling involves movement of cargo through tubular regions 
of EE to recycling endosomes (RE) expressing Rab11.  Cargo in RE is recycled to the 
plasma membrane or transported to the trans-golgi network (TGN).  Vesicular regions 
of the EE are delivered to late endosomes (LE) expressing Rab7 and Rab9.  Final 
degradation of cargo in LE occurs following delivery to lysosomes (L). 
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characterized by their low pH, level of expression of specific glycoproteins including 
lysosome membrane glycoproteins (lgps) and lysosome-associated membrane proteins 
(lamps), as well as a high density on Percoll (38).  In order to function properly, Rab 
GTPases must cycle between the active GTP-bound and inactive GDP-bound states.  In 
the GTP-bound, active form, Rab proteins recruit specific effector proteins to the 
membrane to perform a variety of functions including membrane budding, fusing, 
docking, or movement along the cytoskeletal network (reviewed in (39, 40)). 
 
Early Endosomes 
 The first stop for newly uncoated vesicles is the EE.  Early or sorting endosomes 
are the crossing guards of the endosomal pathway, sorting cargo from all budding 
vesicles (37, 41).  EE are dispersed throughout the cytoplasm and contain two 
morphologically different domains, tubular regions and vesicular regions (42).  The 
tubular regions are generally 50-60 nm in diameter and up to 4 µm in length (43), while 
the vesicular regions range from 400-700 nm in diameter (44).  Cargo can exit EE along 
several different pathways, including movement to RE, LE and lysosomes, or to the 
trans-Golgi-network (TGN).  Association of cargo with the endosomal membrane is 
thought to mediate these initial sorting events.  Receptors and other membrane proteins 
occupy a large surface area within the endosomes, and are therefore transported to RE 
through tubular regions.  Soluble cargo, on the other hand, require more fluid volume, 
but little association with the membrane, and are therefore transported to LE through 
vesicular regions (1, 45).   
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 The pH of EE, ranging from 6-6.5 (46-48), is low enough to dissociate certain 
ligands from receptors, such as the low density lipoprotein (LDL) and Tf, but high 
enough to leave receptors intact to allow for recycling back to the surface, like the low 
density lipoprotein receptor (LDLR) and TfR (49).  EE express several Rab proteins, 
based on the destination of the cargo.  These include Rab5, Rab4, and, to a lesser extent, 
Rab11. 
 The small GTPase Rab5 is a key regulator of early endocytosis, including 
movement from clathrin-coated vesicles to EE as well as fusion between early 
endosomal compartments (39, 50-52).  Uncoated vesicles move first into Rab5-positive 
endosomes, which then fuse to each other and move to the early endosomal 
compartment.  Rab5 also plays a direct role in the association and movement of EE 
along microtubules (53). 
 Rab4 is expressed in both EE and RE, and is involved in early sorting events as 
well as rapid recycling of membrane proteins from EE to the plasma membrane (39, 
54).  Rab4 localizes to both vesicular and tubular regions of the EE and requires cycling 
between membrane-bound and unbound forms into order to function properly (55).  
Rab4 is also thought to work with Rab5 to help maintain a balance in trafficking 
between the plasma membrane and endosomes (56).  This cooperation has been proven 
further with the discovery that the Rab5 effector protein Rabaptin-5 also binds to Rab4 
(57). 
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Recycling endosomes 
 REs, located in the perinuclear cytoplasm, are thought to arise from the tubular 
extensions of EE, as mentioned above.  There are two different types of recycling 
pathways, rapid recycling and slow recycling.  Rapid recycling directly from the EE to 
the plasma membrane is thought to involve initial localization with Rab4-enriched 
regions of the EE, followed by movement to the plasma membrane.  Slow recycling 
involves movement to perinuclear RE (pH 6.4-6.7) located near the microtubule-
organizing center (48, 58). 
 Rab11 is expressed in slow-recycling endosomes and perinuclear RE and 
regulates traffic at the TGN/RE boundary (59-61).  Activation of Rab11 by GTP is 
necessary for the delivery of membrane proteins, including the TfR, to the plasma 
membrane from perinuclear RE (59, 61).  Rab11 also plays a role in early endosomal 
compartmentalization, so that proteins can be delivered to the appropriate 
compartments, including REs and the TGN (62). 
 
Late endosomes and lysosomes 
 Movement from EE to LE involves the budding and dissociation of vacuolar 
regions of EE into carrier vesicles (63), which travel along microtubules to the 
perinuclear cytoplasm (44).  These carrier vesicles may contain several internal vesicles 
and are therefore also termed multivesicular bodies (64).  LEs, defined by the 
accumulation of multiple carrier vesicles, are enriched for the mannose-6-phosphate 
receptor (MPR), Rab7, and Rab9 (65, 66). 
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 Rab9 is expressed in and regulates trafficking within late endosomes (39, 60).  
Depletion of Rab9 leads to a decreased number of LE and lysosomes.  Additionally, in 
the absence of Rab9, LE and lysosomes localize closer to the nucleus.  Thus, Rab9 
plays an important role in regulating LE size, number, and endosomal location (67).  
Rab9 is also involved in the transport of MPR from LE to the TGN and, as such, 
involved in lysosome biogenesis (68-70).  MPR plays an important role in delivering 
lysosomal enzymes to and from LE and the TGN.  Without Rab9, MPR does not 
recycle between the two compartments and lysosomal enzymes are inefficiently sorted 
(69). 
 Following trafficking to LE, cargo is delivered to lysosomes.  Lysosomes 
function as the final degradative compartment for many cellular processes, including 
material internalized via endocytosis, phagocytosis (phagolysosomes), and autophagy 
(38).  Lysosomes are characteristically very similar to LE, as both express lgps and 
lamps and both contain acid hydrolases.  However, when compared to LE, lysosomes 
have a higher density on Percoll due to increasing digested material, contain more 
active acid hydrolases, have a lower pH (pH 4.5-5 versus pH 5-6) (6, 46, 48), no longer 
express MPR, and express higher levels of lgps and lamps (38, 65). 
 
C.  RECYCLING OF THE TRANSFERRIN RECEPTOR 
 One of the most well-characterized internalization pathways is the recycling 
pathway of the TfR and its ligand Tf.  Most of what we know about recycling 
endosomes, endosomal sorting, and receptor-mediated internalization has been derived 
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from studies of the TfR/Tf pathway.  Brief descriptions of the receptor, ligand, and 
internalization pathway are given below. 
 The TfR is a transmembrane glycoprotein that exists as a homodimer on the 
surface of most cells (71).  The TfR binds to the serum glycoprotein Tf to deliver iron 
into cells.  Each receptor can bind two molecules of Tf (71), with a similar relative 
affinity of 7-13 x 10-9 M-1 for either iron-bound (diferric) Tf at pH 7.0 or iron-depleted 
(apo) Tf at pH ~5.4 (72).  Expression of the TfR is dependent on the amount of 
extracellular iron available, as receptor numbers are decreased when cells are grown in 
iron-rich media, and vice-versa (73, 74). 
 Tf is a serum glycoprotein that delivers iron to most body tissues (73, 75).  Tf 
contains two iron-binding sites, which bind to iron with very high affinity at pH 7.0 and 
low affinity at low pH (75).  When bound to two molecules of iron, diferric-Tf binds to 
the TfR with high affinity (72), and the complex is internalized via clathrin-mediated 
endocytosis.  Although this process occurs constitutively, regardless of whether the 
receptor is bound to ligand (76), recycling rates are significantly increased when the 
receptor is bound to Tf or to a TfR-specific antibody, due to an increase in Ca2+ influx 
(76). 
 Endocytosis of the TfR does not involve recruitment of adaptor proteins, but 
rather involves movement of the complexed receptor to already formed clathrin-coated 
pits, as the TfR is permanently associated with the clathrin adaptor protein, AP-2, via a 
cytoplasmic tyrosine-containing motif (77).  This allows for rapid internalization from 
the cell surface.  Once internalized, the complex localizes to Rab5- and Rab4-positive 
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EE within 2-4 min.  Iron is released from the Tf/TfR complex in EE, leaving the TfR 
bound to iron-depleted (apo) Tf, due to its high affinity for the receptor at low pH (72).  
From here, the complex can directly recycle to the plasma membrane via Rab4 and the 
fast-recycling pathway or move to Rab11-positive RE (5-7 min) through the slow-
recycling pathway (58).  These REs translocate to the perinuclear cytoplasm, near the 
microtubule-organizing center.  From there, traffic continues to the plasma membrane 
(10-12 min) where apo-Tf is released to bind more iron (6, 45). 
 
D.  ANTIBODIES AS THERAPEUTICS 
 The use of antibodies to target specific cells or cell types has become an 
increasingly popular method of treatment for a variety of diseases.  Targets for 
antibody-mediated internalization include both endogenous cell surface proteins as well 
as virus-associated surface proteins.  In order for an antibody or antibody-conjugate to 
be functional, it must internalize and localize with EE, LE, and lysosomes, so that the 
antibody/protein complex will be degraded or, in the case of a drug-conjugate, the drug, 
will be released into the cytoplasm (78-80).  Many studies examining the potential of an 
antibody to be used as a therapeutic either focus on determining whether or not an 
antibody will localize with LE (78, 81) or involve the use of antibodies that recognize 
proteins known to internalize through a degradation pathway, e.g. the epidermal growth 
factor receptor (EGFR). 
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Antibody-mediated internalization of cellular proteins 
 Studies have shown that the use of antibodies to target cellular proteins can be 
beneficial for the treatment of various diseases and cancers.  The presence of antibodies 
specific for the β-amyloid peptide on the surface of neuronal cells, which can mediate 
internalization and degradation of the protein (80), have been shown to slow cognitive 
deterioration and reduce plaque burden in mice and Alzheimer’s patients (82-84).  
Several groups have shown that antibodies against altered growth factor receptors or 
adhesion molecules can be utilized in targeting specific cell types or cells within a 
particular activation state to suppress gene expression (78, 85, 86).  For example, 
monoclonal antibodies conjugated to cytotoxic drugs can slow development of 
choroidal neovascularization (CNV), the major complication associated with macular 
degeneration, through targeting the integrin molecule α4β3, which is highly expressed 
in CNV membranes (87).  Additionally, antibodies conjugated to chemokines/cytokines 
have been shown to decrease tumor formation in a cancer model and decrease 
inflammation in a rheumatoid arthritis model, by targeting the EMD domain of 
fibronectin, which is highly expressed in tumor cells and at sites of arthritis (81, 88). 
 
Antibody-mediated internalization of viral proteins 
 Studies have also indicated the benefit of using antibodies to treat viral 
infections.  Virus-specific antibodies are known to modulate or neutralize viral infection 
and decrease virus-induced cell death (89).  One potential mechanism for inhibiting 
viral release is to mediate the internalization of the viral glycoproteins expressed on the 
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surface of infected cells.  It is possible that this internalization renders virus within a 
cell unable to appropriately bud from an infected cell, leading to a decrease in viral 
titers and an ineffective viral infection (90, 91).  Additionally, it has been shown that 
antibody-mediated internalization of viral proteins could be used to target antiviral 
therapeutics to infected cells only.  For example, Song et al. reported that an antibody 
against the HIV glycoprotein can specifically deliver functional siRNA only to infected 
cells, leading to a decrease in viral protein expression (79).  Others have shown that 
antibodies directed against the hepatitis B surface antigen can effectively deliver 
antiviral siRNAs to infected cells both in vitro and in vivo leading to decreased viral 
gene expression (92). 
 
E.  IMMUNE RESPONSE TO INTERNALIZED MATERIAL 
 Internalization of cargo via the pathways listed above usually represents a single 
event with no further cellular consequences other than those directly associated with the 
event, such as iron delivery via TfR/Tf complexes.  However, certain internalization 
events, especially those involving the phagocytosis pathway, can also activate the host 
immune system, depending on the cargo and the associated cell.  As mentioned above, 
neutrophils, monocytes, and macrophages are the major cell types involved in 
phagocytosis.  Their ability to recognize and respond appropriately to phagocytosed 
material is necessary for proper maintenance and activation of the innate immune 
response.  Aberrations in this response can cause debilitating disease and autoimmune 
disorders. 
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The role of macrophages in immune recognition 
 Neutrophils and monocytes, generated in the bone marrow, enter the circulation 
in response to hematopoietic and chemotactic factors.  After up-regulation of adhesion 
molecules on endothelial venules (93), these cells can rapidly migrate to sites of tissue 
damage (94).  Neutrophils are generally short-lived, around 1 to 2 days, and are 
considered ‘first-responders’, as they arrive to sites of inflammation hours before 
monocytes (93).  Because of this rapid response, neutrophils represent the hallmark of 
an acute inflammatory response.  Monocytes, which in the presence of various 
chemokines and cytokines differentiate into macrophages, can remain in the circulation 
for days, weeks, even years (8), representing a more robust, sustained, inflammatory 
response (94). 
 Innate immune cells, especially monocytes and macrophages, express several 
different types of receptors in order to appropriately respond to foreign material.  These 
include Fc- and complement-receptors as well as receptors specific for particle- or 
pathogen-associated molecular patterns (PAMPs).  These receptors, referred to as 
pattern recognition receptors (PRRs), include TLRs, which are expressed on both the 
cell surface and endosomal membranes, and NLRs (nucleotide-binding domain, 
leucine-rich repeat containing receptors – formally termed NOD-like receptors), which 
are expressed in the cytosol.  TLRs are transmembrane proteins that contain an 
extracellular leucine-rich repeat (LRR) domain, and an intracellular Toll/interleukin-1 
receptor (TIR) domain (95).  TLRs recognize a wide variety of PAMPs including LPS, 
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peptidoglycans, flagellin, and microbial/viral RNA or DNA (96).  Recognition of 
PAMPs by TLRs occurs through the C-terminal LRR domains (95), which induces 
recruitment of adaptor molecules to intracellular TIR domains, leading to downstream 
signaling events including activation of MAP kinases, interferon-responsive factors 
(IRFs), and the NF-κB response (97). 
 
NLR proteins and inflammasomes 
 Structurally, NLRs usually contain an N-terminal effector domain [pyrin domain 
(PYD), caspase recruitment domain (CARD), or baculovirus inhibitor of apoptosis 
(BIR) domain], a central nucleotide-binding domain [domain present in neuronal 
apoptosis inhibitory protein (NAIP), CIITA, HET-E, and TP1 (NACHT)], and a C-
terminal receptor domain composed of LRRs (98).  NLRs, like TLRs, recognize 
molecular patterns through their LRR domains (99).  NLRs normally exist in the cytosol 
in an inactive conformation.  The LRRs fold back onto the NACHT domain, inhibiting 
oligomerization of the NACHT domains.  Once NLRs are exposed to ligands through 
interaction with LRRs, a conformational change occurs, exposing the NACHT domain 
and triggering oligomerization, which is required for activation (98).  Following 
oligomerization, NLRs recruit caspases, adaptor proteins, or kinases through homotypic 
interactions with the effector domain and proteins expressing a CARD, PYD, or BIR 
domain, depending on the NLR (98).  Through oligomerization and adaptor molecule 
recruitment, these proteins have been observed to form large molecular complexes in 
the cytosol, termed inflammasomes (100).  The NLR family can be divided into two 
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major sub-families, the CARD-containing NODs and PYD-containing NLRPs (formally 
termed NALPs).  To date, there are currently 14 known human NLRPs (101) which 
have been shown to recognize a variety of molecular ligands such as MDP, anthrax 
lethal toxin, flagellin, ATP, and Nigericin, as well as various live pathogens including 
Candida albicans, Staphylococcus aureus, Salmonella typhimurium, Legionella 
pneumophila, and Listeria monocytogenes (102, 103). 
 
NLRP3 recognition of particulate material 
 The NLRP3 inflammasome has been shown to be involved in the inflammatory 
response to particulates including silica, asbestos, monosodium urate (MSU) crystals, 
and cobalt/chromium metal alloys (104-107).  The process leading to NLRP3 activation 
begins with internalization of the particles by phagocytosis.  Phagosomes containing 
internalized particles generally fuse with lysosomes, creating phagolysosomes. 
 Following uptake, the actual trigger for NLRP3 activation and oligomerization 
is unknown, however it is unlikely to be a direct ligand interaction, due to the broad 
range of known stimuli.  There are two major models for NLRP3 activation; the first 
involves interaction with ROS.  ROS are highly reactive free radicals that are produced 
from a variety of cellular processes including oxygen synthesis, NADPH oxidase 
activity and innate immune activation (108).  In order to regulate the amount of ROS in 
cells, which can induce cell damage at high levels, enzymes with anti-oxidant activities, 
such as thioredoxin, will neutralize ROS (108).  Studies have indicated that a 
 20 
thioredoxin interacting protein, TXNIP, can directly bind to NLRP3 in the presence of 
ROS, leading to activation and formation of the inflammasome complex (109).   
 The alternative model is that NLRP3 senses changes in membrane integrity and 
membrane disruption (102).  It is thought that uptake of a large amount of particles 
induces phagolysosomal destabilization and eventually rupture of the lysosomal 
compartment, leading to release of lysosomal contents, including cathepsins, into the 
cytosol (104, 110).  In this model, NLRP3 is activated following an interaction with 
cathepsins, leading to formation of the inflammasome complex (111). 
 As mentioned previously, activation of the NLRP3 inflammasome (Figure 1.2) 
involves a conformational change in NLRP3 into its active form, which then associates 
with the adaptor protein ASC (112) through PYD interactions.  This complex leads to 
the recruitment of pro-caspase-1 through CARD interactions (98, 99, 113).  Pro-
caspase-1 is cleaved into its active form, caspase-1.  Active caspase-1 cleaves pro-IL-1β 
into its active, secreted form, IL-1β.  Secreted IL-1β can bind to and activate the IL-1 
receptor (IL-1R), leading to additional pro-inflammatory signaling, including NF-κB 
activation, pro-inflammatory cytokine production, and neutrophil recruitment.  
Polymorphisms in NLRP3 are linked to a spectrum of auto-inflammatory diseases with 
unchecked IL-1 production, termed cryopyrinopathies (114).  These diseases, which 
include Muckle-Wells syndrome, familial cold autoinflammatory syndrome, and 
chronic infantile neurologic cutaneous articular syndrome, usually present with periodic 
episodes of fever and neutrophil-mediated inflammation, sometimes causing arthritis 
and joint destruction (115). 
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Figure 1.2:  NLRP3 activation and inflammasome complex formation.  
Internalization of a particle (P) induces the production of reactive oxygen species (ROS) 
and cathepsin B release, which activate NLRP3.  Active NLRP3 forms a complex with 
ASC through pyrin domain (PYD) interactions.  ASC then activates and recruits 
caspase-1 through caspase recruitment domain (CARD) interactions.  Active caspase-1 
cleaves pro-IL-1β into active, secreted IL-1β, which can bind to and activate its 
receptor, IL-1R, causing an acute inflammatory response and neutrophil recruitment. 
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Role of IL-1 in immune cell activation 
 IL-1 is a multifunctional cytokine.  It affects most cell types and also influences 
the expression and production of other cytokines.  There are two major forms of IL-1, 
IL-1α and IL-1β.  Both forms are produced as a precursor (pro) form, without a signal 
peptide (116).  Pro-IL-1α is fully active, and is usually found dispersed throughout the 
cytoplasm of cells.  The reverse is true for pro-IL-1β, which is inactive until cleaved by 
caspase-1 (116).  Although IL-1α can be found outside of cells in regions of high 
inflammation, functions for IL-1α are mainly intracellular.  For example, following 
stimulation with cytokines and TLR ligands, intracellular pro-IL-1α translocates to the 
nucleus, where it participates in activation of NF-κB and AP-1 and induces the 
synthesis of pro-inflammatory cytokines, including IL-6 and more IL-1α (116-118). 
 Gene expression and generation of mature, secreted IL-1β is much more tightly 
regulated than IL-1α, as its functions are much more broad and, likely, systemic.  Gene 
expression regulation includes specific promoter binding sites, transcriptional 
repressors, and mRNA stabilizers (116).  Once synthesized, further regulatory steps are 
taken to ensure appropriate control of cleavage to the active, secreted form.  In vitro, 
two signals are required for optimal production and cleavage of pro-IL-1β into secreted 
IL-1β (102, 119, 120).  The first signal, which up-regulates pro-IL-1β, can be achieved 
through NF-κB activation by PRR interactions.  The most common first signal used in 
vitro is bacterial LPS, which is recognized by TLR4.  The second signal requires 
caspase-1 cleavage and activation through NLRP-inflammasome induction.  In order for 
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caspase-1 to cleave pro-IL-1β, it must first be activated through self-cleavage of pro-
caspase-1 (121), introducing another regulatory step. 
 Both IL-1α and IL-1β can be secreted by a number of cells including 
macrophages, monocytes, neutrophils, lymphocytes, and epithelial cells (122).  IL-1α 
and IL-1β both signal through the type 1 IL-1R.  The IL-1R is a high affinity, 
transmembrane receptor expressed on a variety of cells, including lymphocytes and 
thymocytes (116, 122).  The IL-1R consists of an extracellular ligand-binding domain, 
organized similarly to members of the Ig-superfamily, and a cytoplasmic region 
containing a TIR domain (122).  Signaling through the IL-1R requires many of the same 
adaptor proteins associated with TLR signaling, including MyD88, IRAK, and TRAF6, 
which leads to NF-κB activation and inflammatory cytokine production (122). 
 As mentioned above, IL-1 signaling and activation plays a major role in a 
variety of pathways.  Two major functions of IL-1β include osteoclast activation (123-
125) and neutrophil recruitment (104, 126-128).  Studies have found that both bone 
resorption, mediated by osteoclasts, and neutrophil recruitment can be inhibited through 
the use of the IL-1R antagonist, IL-1Ra.  IL-1Ra is produced as two major forms, 
soluble (sIL-1Ra) and intracellular (icIL-1Ra), following cellular stimulation (116).  
sIL-1Ra competes with both IL-1α and IL-1β for binding to the IL-1R. 
 It is thought that since IL-1Ra has only one functional binding site for the 
receptor, while IL-1α and IL-1β have two, IL-1Ra can bind to the IL-1R without 
causing downstream signaling and activation (129).  Commercially available sIL-1Ra, 
known as Anakinra™, has proven to be highly effective at improving joint function in 
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rheumatoid arthritis patients (130-132).  Additionally, treatment of animals with sIL-
1Ra has been highly effective at reducing the severity of inflammation in a variety of 
inflammation models (105, 133). 
 
F.  THESIS OBJECTIVES 
 As described above, endocytosis and phagocytosis pathways are important for 
many cellular functions.  Both pathways involve internalization of cargo, followed by 
movement through portions of the endocytic compartments.  These pathways differ, 
however, in the downstream implications of internalization.  Endocytosis pathways (or 
receptor-mediated internalization in non-phagocytic cells) are utilized for cell survival, 
receptor recycling, and other maintenance functions, whereas phagocytosis pathways 
(or internalization of cargo by professional phagocytes) are utilized for the protection 
and defense against non-self, including pathogens and particulate material.  
Understanding the mechanisms surrounding these two essential functions of cells will 
aid in the development of targeted therapeutics for a variety of applications, including 
viral inactivation and clearance, pathogen removal, anti-cancer therapies, and many 
more. 
 In this thesis, the roles of endocytosis and phagocytosis pathways in a variety of 
clinically relevant scenarios will be examined:  antibody-mediated internalization of 
cell-surface proteins, titanium wear-particle uptake in failed joint replacements, and 
immune responses to polymeric microparticle uptake for drug delivery or adjuvant use.  
The specific aims of each are explained below: 
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Project 1.  Divergence of surface proteins into a degradation pathway by antibody 
binding. 
 Through understanding receptor-mediated endocytosis pathways and 
characterizing the endosomal compartments within cells, the ability to use antibodies to 
mediate the internalization of surface proteins has become an increasingly popular 
therapeutic avenue.  However, it is still unclear as to how antibodies direct the 
internalization of proteins into a particular endosomal pathway.  One major question 
remains:  Does the surface protein or the ligand specify the internalization pathway?  In 
order to answer this, work described herein will aim to determine whether an antibody 
can alter the internalization pathway of the TfR, which internalizes through recycling 
endosomes when bound to its ligand, Tf.  Work will also examine whether antibody-
mediated internalization can be utilized to target rabies virus infected cells through the 
use of a viral glycoprotein-specific antibody and cells expressing the rabies 
glycoprotein on the surface. 
 
Project 2.  Characterizing the innate immune response to titanium wear-particles. 
 Osteolysis of bone surrounding joint replacements is a major clinical problem 
affecting approximately 10% of all joint replacement patients (134, 135).  Studies have 
shown that small wear particles, generated through normal use, become dislodged and 
released into the tissues surrounding the joint, where they can be taken up by monocytes 
and macrophages (135, 136).  These cells become activated, releasing various pro-
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inflammatory cytokines including IL-1β, suggesting a role for the NLRP3 
inflammasome in inflammation and subsequent bone loss.  Titanium remains an 
important alloy used in many hip and knee replacements and high levels of titanium 
wear-particles are often found in tissues (137, 138).  The NLRP3 response to titanium 
wear particles has not previously been characterized.  The work described here will aim 
to identify if the NLRP3 inflammasome plays a role in the inflammatory response to 
phagocytosed titanium wear particles. 
 
Project 3.  Examining the role of surface curvature in innate immune activation by 
synthetic microparticles. 
 Polymeric microparticles have been widely investigated as platforms for drug 
delivery, adjuvants, and as imaging contrast agents.  Certain types of particles are 
phagocytosed by macrophages more efficiently than others (139).  Additionally, 
different particles can induce significant inflammation or may be relatively well 
tolerated.  However, the physical and chemical characteristics that determine the uptake 
and subsequent immune response to different particles remain undefined.  In order to 
utilize microparticle technology to its full potential, it is essential to understand the 
ability of such particles to either activate or inhibit an immune response following 
uptake.  Work described in this section will aim to define the role of microparticle shape 
in activating the immune response, which has important implications for engineering of 
delivery vehicles and implant materials. 
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CHAPTER II 
Divergence of surface proteins into a degradation pathway by antibody binding 
 
INTRODUCTION 
The use of antibodies to target specific cells or cell types has become an 
increasingly desirable method of treatment for a variety of diseases.  The presence of 
antibodies specific for the β-amyloid peptide on the surface of neuronal cells, which can 
mediate internalization and degradation of the protein (80), have been shown to slow 
cognitive deterioration and reduce plaque burden in mice and Alzheimer’s patients (82-
84).  Antibodies against altered growth factor receptors or adhesion molecules have also 
been utilized in targeting specific cell types or cells within a particular activation state 
to suppress gene expression in cancerous tissues (78, 85, 86).  In order for an antibody 
to efficiently promote the internalization and subsequent degradation of target surface 
proteins, it must be delivered to a low pH, late endosomal or lysosomal compartment 
associated with the degradation pathway (78-80).  Due to the broad-range of cell surface 
proteins that have been successfully utilized for antibody-based internalization or 
delivery, we hypothesized that the internalization pathway observed when an antibody 
is bound to a cell surface protein may remain the same, regardless of the natural 
internalization pathway of the membrane protein to which the antibody is specific.  In 
order to examine this, we analyzed the internalization of an endogenous cell surface 
protein, the transferrin receptor, when bound to an antibody (αCD71) and compared this 
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to the well-known, recycling pathway observed when the receptor is bound to its ligand, 
transferrin. 
Antibody-mediated delivery has also been exploited to target virus-infected cells 
and deliver antiviral agents, while sparing uninfected cells, using cell surface-expressed 
viral proteins (79, 92).  It is known that glycoprotein-specific antibodies can mediate 
internalization of viral glycoproteins (89, 140-142), and studies have suggested that the 
ability of antibodies to inhibit viral release from infected cells is partially due to the fact 
that it efficiently binds to and internalizes the envelope protein to which it is specific 
(89, 90).  This mechanism of inhibition has been shown to be effective with influenza 
virus-infected cells and antibodies specific for the virus envelope protein, 
neuraminidase (91).  To examine whether antibodies can be utilized to mediate the 
internalization of the rabies virus glycoprotein (G), we characterized the internalization 
of a rabies G-specific antibody, termed ARG1, in cells expressing rabies G on the 
surface.  To define whether the antibody-bound glycoprotein would be delivered to a 
degradative pathway, we analyzed its co-localization with known markers of the 
degradative pathway, including the Rab GTPase Rab9 and low pH lysosomes. 
We find that transferrin bound to the transferrin receptor and ARG1 bound to 
rabies G follow distinctly different endocytic pathways.  However, when an antibody is 
used to target the transferrin receptor, it is diverted to the pathway followed by the 
antibody-bound rabies G.  Thus, we theorize that antibody binding can overcome the 
endosomal sorting signals inherent to cell surface proteins and mediate their delivery to 
a generalized antibody-mediated degradative pathway. 
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B.  MATERIALS AND METHODS 
Cells and cell culture: 
MNA cells (generous gift of Massachusetts Biologic Laboratories) and HEK293T cells 
(ATCC) were grown in complete medium (Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, 
1% L-glutamine, and 1% sodium pyruvate) at 37˚C with 10% CO2.  For antibody 
binding and localization experiments, 60-80% confluent cells were transfected with 1 
µg of Rabies G-, clathrin-GFP-, or Rab-XFP-expressing plasmids using GeneJuice 
reagent (Novagen) according to the manufacturer’s protocol.  Cells were imaged 24 h 
after transfection. 
 
Plasmids: 
The Rabies G glycoprotein expression plasmid, a generous gift from Massachusetts 
Biologic Laboratories, has been previously characterized (143).  Fluorescently tagged 
Rab4, Rab9, and Rab11 expression plasmids were provided by Eicke Latz (University 
of Massachusetts, Worcester, MA).  To generate dominant negative Rab5a (S34N), site-
directed mutagenesis was performed on a GFP-tagged Rab5a expression plasmid using 
a Phusion site-directed mutagenesis kit (Finnzymes). 
 
Antibodies and reagents: 
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ARG1 antibody (gift from Massachusetts Biologic Laboratories) was purified from 
hybridomas generated from rabies vaccine-immunized HuMAb (Medarex) mice, as 
described previously (143).  Mouse anti human CD71 (αCD71) antibody was obtained 
from BD Biosciences.  Antibodies were directly labeled with Alexa Fluor 647 (for 
confocal studies) or Alexa Fluor 568 (for TIRF studies) using Alexa Fluor protein-
labeling kits (Molecular Probes, Invitrogen).  Fluorescent human Tf and LysoTracker 
Green DND-26 were obtained from Molecular Probes (Invitrogen).  LA, used at a 
concentration of 1.25 µM for inhibition studies, was purchased from Sigma. 
 
Flow Cytometric Analysis: 
Cells were grown to subconfluency on 6-well dishes (Falcon) in complete medium.  
Cells were resuspended in FACS buffer (PBS containing 1% BSA and 0.01% sodium 
azide) and surface stained with indicated antibodies for 1 hour at 4˚C.  When necessary, 
secondary anti-human IgG-APC (Invitrogen) was added to cells for 1 hour at 4˚C in 
FACS buffer.  Following staining, cells were washed with PBS and analyzed on a 
LSRII (BD Biosciences).  Data were acquired by DIVA (BD Biosciences) and were 
analyzed with FlowJo 8.8.6 software (Tree Star Inc.). 
 
Confocal Microscopy: 
Cells were cultured on glass-bottom 35-mm tissue-culture dishes (MatTek) in complete 
medium.  Images were taken on a Leica SP2 AOBS confocal laser-scanning microscope 
with a 63x objective, using Leica Confocal Software.  Multicolor images were acquired 
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by sequential scanning with only one laser active per scan to avoid cross-excitation.  
Overall brightness and contrast of images were optimized using Adobe Photoshop CS3. 
 
TIRF Microscopy: 
Cells were cultured on 25-mm coverslips (Thomas Scientific, No. 1.5) in complete 
medium.  Cells were transferred from complete medium to KRH (125 mM NaCl, 5 mM 
KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 25 mM HEPES pH 7.4, 2 mM sodium pyruvate, 
and 0.5% BSA (bovine serum albumin)) just prior to imaging, at 35°C.  Two Coherent 
Innova 70C lasers were used.  Argon ion and argon-krypton ion lasers were used to 
produce the 488 and 568 nm light, respectively.  The combined beams were coupled 
into a single mode fiber using a KineFLEX fiber coupler manufactured by Point Source 
(Hamble, UK).  A modified Olympus IX81 inverted microscope, a modified Olympus 
TIRF fiber illuminator and an Olympus Plan APO 60x objective with a numerical 
aperture (NA) of 1.45 were used.  TIRF illumination was introduced through the edge 
of the objective at an angle set between 65° and 68° giving a penetration depth of 90-
121 nm at 488 nm and 105-141 nm at 568 nm.  Light was collimated through the 
objective and a layer of immersion oil onto the coverslip.  The quality of the collimation 
was set halfway between the best for 488 nm and 568 nm.  Light from the fluorophores 
was collected and relayed onto a 640x448 pixel CCD camera developed with Lincoln 
Labs (MIT).  A Physik Instruments pifoc was used for fine focus control.  The entire 
microscope was contained in a heated chamber held at 35°C.  Imaging hardware and 
software were previously described (144). 
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Co-localization analysis: 
The total number and percent of co-localized pixels per image was calculated as 
described previously (144, 145).  Briefly, single fluorophore raw images were corrected 
by subtracting the background fluorescence outside the cell.  Next, regions of potential 
co-localization were cropped and saved as new files for analysis.  From this, the 
intensity of all positive-valued pixels was set to one and all other pixels to zero to 
generate a binary masking image.  Co-localized pixels were identified from the overlap 
of the masked images of each fluorophore.  Non-specific (background) co-localization 
was defined as that seen when pixel-rich regions were rotated 180 degrees relative to 
each other (flipped images).  
 
Statistical Analysis: 
A two-way ANOVA followed by Bonferroni’s correction for post-test comparisons was 
used to determine statistical significance.  Values of p < 0.05 were considered 
significant.  Statistics were performed using GraphPad (Prism v5.0a) software. 
 
C.  RESULTS 
Internalization and endosomal localization of the transferrin receptor/transferrin 
complex 
 It has been suggested that in order for a therapeutic antibody to mediate 
degradation of its target protein or to specifically deliver compounds into cells, the 
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internalization pathway must occur through receptor-mediated endocytosis, including 
localization with clathrin, early endosomes, late endosomes and/or lysosomes, 
associated with the degradation pathway (78-80).  
 We examined the internalization pathway of an endogenous cell surface protein, 
the transferrin receptor (TfR), bound to an antibody or to its ligand, transferrin (Tf).  We 
first verified the natural internalization pathway of the TfR in HEK cells.  TfR bound to 
Tf is known to internalize via clathrin-coated vesicles almost exclusively through a 
recycling pathway (58, 146, 147).  To examine localization with clathrin, fluorescent Tf 
was added to HEK cells transfected with clathrin-GFP.  Tf localization to clathrin was 
examined using total internal reflection fluorescence (TIRF) microscopy, an imaging 
technique in which fluorophores residing within approximately 100-300 nm from the 
plasma membrane can be selectively excited (145, 148, 149).  In order to determine 
localization, we examined the total number and the percent of Tf and clathrin co-
localized pixels over a 20 min time course.  As expected, Tf localized with clathrin very 
rapidly after addition to cells, consistent with published findings (144) (Figure 2.1a).  
TIRF analysis revealed a mean (± S.D.) of 220.5 (± 94.7) total and 31.21 (± 11.89) 
percent Tf co-localized pixels, respectively.  This was higher than background co-
localization (flipped images), which exhibited a mean (± S.D.) of 20.88 (± 23.64) total 
and 2.692 (± 2.4) percent co-localized pixels.  Background co-localization was 
calculated when the images (Tf and clathrin) were flipped 180 degrees relative to each 
other. 
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Figure 2.1:  Ligand and antibody-mediated internalization of the TfR localizes 
with clathrin.  (A, B) HEK cells were transfected with clathrin-GFP followed by 
incubation with either transferrin (Tf, A) or antibody (αCD71, B).  Graphs show the 
total number (left) or percent (right) of co-localized pixels from addition to cells (T = 0 
or 400) to 20 min following addition (T = 1200).  Images on the left show the total 
number of Tf (A) or αCD71 (B) pixels that are co-localized with clathrin.  Images on 
the right show the percent of Tf (A) or αCD71 (B) pixels co-localized with clathrin as 
well as the percent of clathrin pixels co-localized with either Tf (A) or αCD71 (B).  
Background co-localization, flipped images, were generated by rotating red and green 
pictures 180 degrees relative to each other.  Images were taken using TIRF microscopy.  
Data are representative of three separate experiments. 
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 The endosomal internalization pathway consists of various endosomal 
compartments that are differentially characterized by their expression of proteins of the 
Rab family of small GTPases, including Rab4, Rab5a, Rab9, and Rab11.  Rab4 is 
expressed in early endosomes and recycling endosomes, and is thought to play a role in 
early sorting events (39, 60).  Rab5a is a key regulator of early endocytosis, including 
movement from clathrin-coated vesicles to early endosomes as well as fusion between 
early endosomal compartments (39, 50-52).  Rab9 is expressed in and regulates 
trafficking within late endosomes (39, 60).  Rab11 is expressed in recycling endosomes 
and regulates traffic at the trans-golgi network/recycling endosome boundary (59, 60).  
To examine endosomal localization of Tf-bound TfR, HEK cells were transfected with 
Rab4-GFP, Rab5a-GFP, Rab9-YFP, or Rab11-GFP expressing plasmids and imaged 
using confocal microscopy.  As expected, when bound to fluorescent Tf, internalized 
TfR localized with the early endosomal markers Rab4-GFP (Figure 2.2a) and Rab5a-
GFP (Figure 2.2b) and the recycling endosomal marker Rab11-GFP (Figure 2.3a) at all 
time points tested, but not with the late endosomal marker, Rab9-YFP (Figure 2.3b).  
This data verifies that, in our system, the TfR/Tf complex internalizes through a 
recycling endosomal pathway. 
 
Endosomal localization of the transferrin receptor/antibody complex 
 We next examined whether or not the internalization of the TfR to recycling 
endosomes would be affected if the receptor were bound to an antibody instead of Tf.  
To mimic an antibody-based therapeutic scenario, we used an antibody specific for the  
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Figure 2.2:  Ligand-mediated transferrin receptor internalization involves early 
endosomes.  HEK cells were transfected with Rab4-GFP (A) or Rab5-GFP (B) and 
incubated with Tf (red) for given time points in complete medium.  Top panels display 
the original image.  Bottom panels display a magnified region of interest (boxed areas 
in top panels).  Data are representative of three separate experiments.  Arrows indicate 
regions of co-localization.  Scale bar: 5 µm. 
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Figure 2.3:  Ligand-mediated transferrin receptor internalization does not involve 
late endosomes.  HEK cells were transfected with Rab11-GFP (A) or Rab9-YFP (B) 
and incubated with Tf (red) for given time points in complete medium.  Top panels 
display the original image.  Bottom panels display a magnified region of interest (boxed 
areas in top panels).  Data are representative of three separate experiments.  Arrows 
indicate regions of co-localization.  Scale bar: 5 µm. 
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exofacial domain of the transferrin receptor protein, αCD71.  As described above, HEK 
cells were transfected with Rab4-GFP, Rab5a-GFP, Rab9-YFP, or Rab11-GFP.  
Surprisingly, when bound to fluorescent αCD71, the TfR/αCD71 complex localized 
with all endosomal markers, including the late endosomal marker, Rab9-YFP (Figures 
2.4 and 2.5), which was not seen in the natural TfR/Tf internalization pathway.  
Internalized antibody also localized with clathrin, similar to that seen with the TfR/Tf 
complex (Figure 2.1b). 
 To quantify the apparent shift in trafficking to include late endosomes, the total 
number of co-localized pixels between the TfR/Tf complex or the TfR/αCD71 complex 
and Rab9-YFP were compared.  The number of co-localized pixels between the TfR/Tf 
complex and Rab9 were at levels similar to background (flipped images) at all time 
points tested, ranging from a mean (± S.D.) of 49.33 (± 17.93) to 116 (± 21.22) total and 
9.84 (± 1.48) to 13.93 (± 1.83) percent co-localized pixels.  Comparatively, the number 
of co-localized pixels between the TfR/αCD71 complex and Rab9 were significantly 
higher (p ≤ 0.01) than background at all time points, ranging from a mean (± S.D.) of 
200.5 (± 34.79) to 422.67 (± 99.86) total and 19.22 (± 3.22) to 24.98 (± 2.35) percent 
co-localized pixels (Figure 2.5b).  These results indicate that, when bound to an 
antibody, the internalization pathway of the TfR can shift from an exclusively recycling 
endosomal pathway to include localization with late endosomes. 
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Figure 2.4:  Antibody-mediated transferrin receptor early and recycling 
endosomal localization is similar to that of the natural pathway.  HEK cells were 
transfected with Rab4-GFP (A), Rab5a-GFP (B), or Rab11-GFP (C) and incubated with 
αCD71 (red) for given time points in complete medium.  Top panels display the 
original image.  Bottom panels display a magnified region of interest (boxed areas in 
top panels).  Arrows indicate regions of co-localization.  Data are representative of three 
separate experiments.  Scale bar: 5 µm. 
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Figure 2.5:  Antibody-mediated transferrin receptor internalization includes 
movement though late endosomes.  A) HEK cells were transfected with Rab9-YFP 
(green) and incubated with αCD71 (red) for given time points in complete medium.  
Top panels display the original image.  Bottom panels display a magnified region of 
interest (boxed areas in top panels).  Arrows indicate regions of co-localization.  Scale 
bar: 5 µm.  B) Analysis of total and percent of Rab9/Tf versus Rab9/αCD71 co-
localized pixels (n ≥ 5 per time point).  Background co-localization (flipped images) 
was generated by rotating red and green pictures 180 degrees relative to each other.  
Data are representative of three separate experiments.  Graphs show mean ± s.e.m.  
Significance values are shown relative to Rab9/Tf levels.  P-values are shown as *** ≤ 
0.0001; ** < 0.01; * <0.05. 
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Internalization of the ARG1/rabies G complex 
 Since antibody-mediated delivery has also been utilized in the treatment of viral 
infections, we examined the internalization and fate of a viral cell surface glycoprotein, 
rabies G, by using a fluorescent rabies-specific antibody, ARG1, which specifically 
binds to and internalizes in mouse neuroblastoma cells expressing rabies G (MNAG) on 
the surface (Figure 2.6).  In order to generate a potential antibody-based therapeutic, it 
is essential to fully understand the internalization pathway of the target protein.  
Although the natural endocytic pathway of the TfR has been well characterized, the 
internalization of the rabies G glycoprotein has not been studied.  We therefore 
performed a more in-depth analysis of the endocytic pathway of ARG1-bound rabies G, 
beginning with its association with clathrin. 
 To examine the role of clathrin in fluorescent ARG1 internalization, MNAG 
cells were transfected with GFP-clathrin and ARG1 localization was assessed by TIRF 
microscopy.  We found that internalized ARG1 quickly localizes with clathrin-GFP 
after addition to cells and remains co-localized through 20 min (Figure 2.7a).  Total co-
localized ARG1 pixels ranged from 220-480 pixels and the percent of ARG1 pixels co-
localized with clathrin ranged from 33-56 percent.  This was significantly higher than 
background localization levels (flipped images), which ranged from 90-270 total and 
18-34 percent co-localized pixels.  We also examined ARG1 localization to clathrin at 
later time points using confocal microscopy.  Similar to TIRF results, internalized 
antibody localized with clathrin up to 30 min after addition to cells (Figure 2.7b, 
arrows) with no localization by 1 hour.  Taken together, these data suggest that the 
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Figure 2.6:  ARG1 specifically binds to and internalizes in Rabies G-expressing 
cells.  A) MNA cells were transfected with Rabies G (red lines), or empty vector 
(dashed lines) and surface stained with indicated humanized antibodies (non-specific or 
ARG1).  Gray plots indicate isotype staining.  B) MNAG cells were incubated with 
ARG1 at 4˚C (top panels) and 37˚C (bottom panels) for given time points in complete 
medium.  Data are representative of two separate experiments.  Scale bar: 5 µm. 
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Figure 2.7:  ARG1 localizes with clathrin-expressing vesicles at early time points 
following addition to cells.  A, B) MNA cells were co-transfected with Rabies G and 
clathrin-GFP.  A) Amount of total and percent ARG1/clathrin co-localized pixels from 
addition to cells (T = 0) to 20 min following addition (T = 1200).  Images were taken 
using TIRF microscopy.  Background co-localization, flipped images, were generated 
by rotating red and green pictures 180 degrees relative to each other.  Arrow indicates a 
wash step.  B) ARG1 (red) was incubated with cells for given time points in complete 
medium and imaged using confocal microscopy.  Top panels display the original image.  
Bottom panels display a magnified region of interest (boxed areas in top panels).  
Arrows indicate regions of co-localization.  Data are representative of three separate 
experiments.  Scale bar: 5 µm. 
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ARG1/rabies G complex internalizes in MNAG cells via a clathrin-mediated 
endocytosis pathway, similar to that seen with other antibody-bound viral glycoproteins 
(89, 141). 
 Studies have indicated that actin polymerization is necessary for receptor-
mediated endocytosis and antibody-directed endocytosis of viral glycoproteins in 
mammalian cells (31, 141).  To examine the role of actin in ARG1 endocytosis, 
internalization was analyzed in the presence of the actin-specific inhibitor, Latrunculin-
A (LA) using confocal microscopy.  When actin polymerization was blocked by LA, 
there was no internal staining at any time point when compared to untreated cells 
(Figure 2.8).  Overall, these results indicate that the ARG1/rabies G complex 
internalizes through a clathrin-associated and actin-dependent mechanism of entry. 
 
Early endosomal localization of the ARG1/rabies G complex 
 To examine early endosomal localization, the role of Rab5a in ARG1 
internalization was assessed in cells expressing wild type Rab5a-GFP through confocal 
microscopy.  Internalized ARG1 localized with Rab5a-positive endosomes at early time 
points after addition to cells (Figure 2.9a, solid arrows), with maximal localization at 15 
min and a complete loss of localization by 1 hour.  To quantify the apparent co-
localization, we also analyzed the total number and percent of co-localized pixels at the 
given time-points.  We saw a significant amount of co-localized pixels at 15 and 30 
minutes, with a mean (± S.D.) of 132.25 (± 18.23) and 81.25 (± 23.52) total pixels, 
respectively.  The amount of ARG1/Rab5a co-localized pixels decreased over time, 
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Figure 2.8:  ARG1 internalization requires actin polymerization.  MNAG cells were 
treated with 1.25 µM of Latrunculin-A (LA treated) or DMSO carrier alone (untreated) 
for 30 min prior to addition of ARG1 antibody (red) in complete medium for given time 
points.  Data are representative of two separate experiments.  Scale bar: 5 µm. 
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Figure 2.9:  Internalized ARG1 localizes to and requires Rab5a-positive 
endosomes.  MNA cells were co-transfected with Rabies G and either WT-Rab5a-GFP 
(A, B) or DN-Rab5a-GFP (C) and incubated with ARG1 (red) for given time points in 
complete medium.  (A) Top panels display the original image.  Bottom panels display a 
magnified region of interest (boxed areas in top panels).  Solid arrows indicate regions 
of co-localization.  (B) Analysis of total and percent ARG1/WT-Rab5a co-localized 
pixels (n ≥ 5 per time point).  (C) Open arrows show internalized antibody.  
Background co-localization, flipped images, were generated by rotating red and green 
pictures 180 degrees relative to each other.  Data are representative of three separate 
experiments.  Graphs show mean ± s.e.m.  Significance values are shown relative to 
background levels.  P-values are shown as *** ≤ 0.0001; * < 0.05; n.s. = not significant.  
Scale bars: 5 µm. 
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with numbers similar to background (flipped images) by 1 to 3 hours ranging from a 
mean (± S.D.) of 29.88 (± 7.66) to 16 (± 4.23) co-localized pixels, respectively (Figure 
2.9b).  The percent of ARG1 pixels co-localized to Rab5a followed a similar pattern, 
with the highest percentage at 15 min (Figure 2.9b). 
 To determine the requirement for functional Rab5a, fluorescent ARG1 
internalization was also assessed in cells expressing a GFP-tagged dominant-negative 
(DN) Rab5a.  In order to function properly, Rab5a must cycle between the active GTP-
bound and inactive GDP-bound states.  The DN form of Rab5a contains a S34N amino 
acid change that is unable to be phosphorylated to the active GTP-bound state and, thus, 
remains GDP-bound (150).  No internalization of ARG1 occurred in the presence of 
mutant (DN) Rab5a, (Figure 2.9c, green cells).  As a control, ARG1 internalization was 
unaffected in cells that did not express GFP and were, therefore, not transfected with the 
DN-form, (Figure 2.9c, open arrows).  These results indicate that ARG1 internalization 
following binding to rabies G localizes with and is dependent on the presence of 
functional Rab5a, a key regulator of endosomal trafficking. 
 
ARG1 localization with Rab4, Rab11, and Rab9 
 To further characterize the intracellular localization of the ARG1/rabies G 
complex, internalization was compared to several different endosomal proteins, Rab4, 
Rab11, and Rab9.  The association of these proteins with fluorescent ARG1 was 
assessed in cells expressing GFP-tagged Rab4 and Rab11 or YFP-tagged Rab9 plasmids 
through confocal microscopy.  ARG1 did not localize with recycling endosomal 
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proteins, Rab4 or Rab11 at any time point tested (Figure 2.10).  However, internalized 
ARG1 began to significantly localize with the late endosomal protein, Rab9 by 1 hour 
after addition to cells, with maximal co-localized pixels at 2 and 3 hours (Figure 2.11) 
exhibiting a mean (± S.D.) of 402.58 (± 45.92) and 432.09 (± 59.79) total and 28.11 (± 
2.39) and 31.46 (± 2.8) percent co-localized pixels, respectively.  Background co-
localized pixels at all time points exhibited a range (± S.D.) of 11.25 (± 7.57) to 86.09 
(± 20.66) total and 1.4 (± 0.99) to 6.65 (± 0.61) percent co-localized pixels (Figure 
2.11b).  To define a possible role for Fc-receptors in antibody internalization or 
trafficking, the internalization of ARG1 F(ab’)2 fragments was assessed.  Fluorescently 
labeled F(ab’)2 fragments of ARG1 exhibited a staining and localization pattern similar 
to that of full length ARG1 (Figure 2.12), indicating that the Fc region of ARG1 does 
not play a role in internalization and endosomal localization. 
 
ARG1 localization with lysosomes 
 Lysosomal localization of the ARG1/rabies G in MNAG cells was also assessed 
through confocal microscopy.  Internalized ARG1 began to localize with the cell-
permeant, acidotrophic dye, LysoTracker Green DND-26, at 1 hour after addition to 
cells (Figure 2.13).  The total number of co-localized pixels increased over time, 
maximal co-localized pixels at 3 hours exhibiting a mean (± S.D.) of 345 (± 55.78) total 
and 33.54 (± 5.39) percent co-localized pixels (Figure 2.13b).  These results indicate 
that the ARG1/rabies G complex traffics from Rab5a-positive early endosomes to  
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Figure 2.10:  ARG1 does not localize with recycling endosomal proteins.  MNA 
cells were co-transfected with Rabies G and either Rab4-GFP (A) or Rab11-GFP (B) 
and incubated with ARG1 (red) for given time points in complete medium.  Top panels 
display the original image.  Bottom panels display a magnified region of interest (boxed 
areas in top panels).  Data are representative of three separate experiments.  Scale bar: 5 
µm. 
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Figure 2.11:  Internalized ARG1 traffics to late endosomes.  (A, B) MNA cells were 
co-transfected with Rabies G and Rab9-YFP and incubated with ARG1 (red) for given 
time points in complete medium.  Top panels display the original image.  Bottom panels 
display a magnified region of interest (boxed areas in top panels).  Arrows indicate 
regions of co-localization.  (B) Analysis of total and percent ARG1/Rab9 co-localized 
pixels (n ≥ 4 per time point).  Background co-localization, flipped images, was 
generated by rotating red and green pictures 180 degrees relative to each other.  Data 
are representative of three separate experiments.  Graphs show mean ± s.e.m.  
Significance values are shown relative to background levels.  P-values are shown as *** 
≤ 0.0001; n.s. = not significant.  Scale bar: 5 µm. 
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Figure 2.12:  F(ab’)2 internalization and endosomal localization is similar to full 
length ARG1.  MNA cells were co-transfected with Rabies G and WT-Rab5a-GFP (A) 
or Rab9-YFP (B) and incubated with F(ab’)2-ARG1 (red) for given time points in 
complete medium.  Top panels display the original image.  Bottom panels display a 
magnified region of interest (boxed areas in top panels).  Data are representative of two 
separate experiments.  Arrows indicate regions of co-localization.  Scale bar: 5 µm. 
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Figure 2.13.  Internalized ARG1 traffics to a lower pH, lysosomal compartment 
within 3 hours.  (A, B)  MNAG cells were incubated with ARG1 (red) and 
LysoTracker Green DND-26 (50 nM) for 30 min in complete medium.  Top panels 
display the original image.  Bottom panels display a magnified region of interest (boxed 
areas in top panels).  Arrows indicate regions of co-localization.  (B) Analysis of total 
and percent ARG1/Lysotracker co-localized pixels (n ≥ 3 per time point).  Background 
co-localization, flipped images, was generated by rotating red and green pictures 180 
degrees relative to each other.  Data are representative of three separate experiments.  
Graphs show the mean ± s.e.m.  Significance values are shown relative to background 
levels.  P-values are shown as *** ≤ 0.0001; ** < 0.01; n.s. = not significant.  Scale bar: 
5 µm. 
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Rab9-positive late endosomes and finally to a lower pH, lysosomal-like compartment 
within 3 hours, similar to that seen with the αCD71-bound TfR, but in contrast to the 
results observed with Tf-bound TfR, which localizes with early and recycling 
endosomes, excluding Rab9, as characterized above. 
 Taken together, our data suggests that binding of an antibody to a cell surface 
protein induces a shift from the natural intracellular trafficking of that protein.  In 
addition, our data proposes that antibodies to any cell surface protein, endogenous or 
viral, mediate predictable trafficking to late endosomal compartments. 
 
D.  DISCUSSION 
 Studies have shown that monoclonal antibodies can be used as a therapeutic 
delivery system to specifically target cells expressing the appropriate receptor protein.  
Several publications have indicated the benefit to using monoclonal antibodies to 
specifically deliver drugs, including the targeted delivery of cytokines and siRNAs to 
tumor cells (81, 85, 87, 88, 151, 152). 
 Critical to the use of antibodies as a drug delivery system is understanding how 
these antibodies traffic and where the complex is localized and/or degraded.  Studies 
have indicated that the use of antibodies as stand-alone or conjugated therapeutics is 
useful to either a) target specific cells for destruction through Fc-mediated killing or b) 
specifically bind to and internalize the cell surface protein to which it is specific.  This 
internalization pathway occurs through receptor-mediated endocytosis, with movement 
from clathrin-coated vesicles to early endosomes to late endosomes and eventually to 
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lysosomes where the antibody and cell surface protein are likely degraded (78, 80, 89).  
Based on these observations, we hypothesized that the internalization pathway seen 
when an antibody is bound to a cell surface protein may remain the same, regardless of 
the natural internalization pathway of the membrane protein to which the antibody is 
specific.  In other words, we theorized that there might be a common antibody-mediated 
internalization pathway that exists when an antibody is bound to a cell surface protein.  
In order to examine this, we analyzed the internalization of an endogenous cell surface 
protein, the TfR.  We observed a significant increase in localization to Rab9-positive 
late endosomes when the receptor was bound to an antibody, indicating that the 
internalization pathway had been shifted to include degradation-associated endosomes, 
in agreement with our hypothesis (Figure 2.14).  As expected, when bound to its natural 
ligand, Tf, the receptor internalized exclusively through a recycling endosomal 
pathway, including localization with endosomal proteins Rab4, Rab5a, and Rab11, but 
not with Rab9.  These results suggest that there is a specific antibody-mediated 
internalization pathway that occurs when an antibody is bound to a cell surface protein. 
 Virus-specific antibodies are known to modulate or neutralize viral infection and 
decrease virus-induced cell death (89).  One potential mechanism for inhibition of viral 
release from infected cells is to mediate the internalization of the viral glycoproteins on 
infected cells.  It is possible that this internalization renders virus within a cell unable to 
appropriately bud from an infected cell, leading to a decrease in viral titers and an 
ineffective viral infection (90, 91).  Additionally, it has been shown that antibody-
mediated internalization of viral proteins can be used to target antiviral therapeutics 
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Figure 2.14:  Diagram of generalized antibody-mediated internalization pathway.  
Antibodies specific for both viral (Rabies G = ARG1) and endogenous proteins 
(Transferrin receptor, TfR = αCD71) mediate localization to Rab9-positive late 
endosomes. 
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specifically to infected cells.  Song et al. reported that an antibody against the HIV 
glycoprotein can specifically deliver functional siRNA to infected cells only, leading to 
a decrease in viral protein expression (79).  Others have shown that antibodies directed 
against the hepatitis B surface antigen can effectively deliver antiviral siRNAs to 
infected cells both in vitro and in vivo leading to decreased viral gene expression (92). 
 Rabies virus infections are worldwide and once the symptoms of rabies develop, 
there is no treatment and the disease is almost always fatal (153).  Disease can be 
prevented by post-exposure prophylaxis, which consists of wound care and 
administration of both the rabies vaccine and rabies immune globulin, which helps to 
neutralize the virus.  Taking advantage of the ability of antibodies and antibody-
conjugates to specifically bind to and subsequently internalize target proteins expressed 
on the surface of cells has broad applicability for the treatment of a variety of viral 
infections.  As such, we examined the antibody-mediated internalization pattern of 
rabies G expressed on the surface of mouse neuroblastoma cells, to mimic an infected 
cell state (154).  Using a rabies G specific antibody, ARG1, we show that the 
ARG1/rabies G complex internalizes via a clathrin- and actin- dependent mechanism, 
followed by movement into endosomes associated with the degradation pathway, 
including localization with Rab5a, Rab9 and low pH lysosomes. 
 Although we have defined a role for actin polymerization in the internalization 
of antibody-bound rabies G, we did not see a requirement for actin in the internalization 
of antibody-bound TfR (data not shown).  It is known that the natural ligand-mediated 
internalization pathway of TfR does not require actin (35, 36).  However, since the 
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αCD71 antibody was able to alter this pathway to include localization with late 
endosomes, we suspected that actin may play a general role in antibody-mediated 
endocytosis.  Surprisingly, the actin inhibitor, LA had no effect on the localization of 
internalized, antibody-bound TfR to Rab9-positive late endosomes (data not shown).  It 
has previously been determined that the TfR localizes to and is internalized via large 
patches of clathrin on the cell membrane (144, 145), allowing for its rapid 
internalization in cells.  This would suggest that, perhaps, actin is required to re-locate 
surface-expressed rabies G to areas on the membrane that would allow for clathrin-
mediated endocytosis.  Since the TfR is already localized to these patches, actin is not 
required, even if internalization occurs via antibody binding, rather than ligand.  Further 
analysis of the role of actin in endocytosis events may shed more light on this 
interesting result. 
 Overall, these findings have broad implications for the use of antibodies as 
therapeutics to either mediate the degradation of cell surface proteins or to be used as 
drug-delivery vehicles, via endogenous and viral cell surface proteins.  As previously 
described, it is thought that in order for an antibody or antibody conjugate to be 
functional, it must internalize and localize with early and late endosomes, and 
potentially lysosomes, so that the antibody/protein complex will be degraded or, in the 
case of a drug-conjugate, the drug, e.g. siRNA or inhibitors, will be released into the 
cytoplasm.  Studies thus far examining the potential of an antibody to be used as a 
therapeutic have either focused on determining whether or not an antibody will localize 
with late endosomes (78) or have involved the use of antibodies specific to proteins 
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known to internalize through a degradation pathway, e.g. EGFR.  Our findings suggest 
that one may not have to choose an antibody therapeutic based on the intrinsic property 
of a cell surface protein, since the binding of an antibody to that protein would guide 
internalization to include the degradative compartments.  This may allow for the 
development of new therapeutics to targets originally overlooked due to their 
internalization pathway, including, but not limited to, recycling receptors. 
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CHAPTER III 
Characterizing the innate immune response to titanium wear-particles 
 
A.  INTRODUCTION 
 With over one million total joint replacements performed every year (136), joint 
replacement surgery is a major advance in treatment of people with arthritis (155).  It is 
estimated that six million total hip and knee replacements will be performed per year in 
the US by 2015 making this a significant health issue.  Long-term studies of hip and 
knee replacements have indicated that loosening of joint replacements, as well as bone-
loss surrounding the replacement, increases over time.  Approximately 10-20% of 
patients who undergo joint replacement surgery will develop joint loosening, eventually 
requiring replacement of the joint (134, 135).  Patients who develop significant 
inflammation surrounding a fixed implant, if left untreated, will eventually develop 
joint loosening and, in some cases, bone loss surrounding the joint.  This type of aseptic 
inflammation is associated with activation of macrophages in the tissue surrounding the 
prosthesis and the destruction of bone.  Studies have shown that over time, small wear-
particles generated from implants become dislodged and are released into the 
surrounding area (135) where they can be phagocytosed by monocytes and 
macrophages (136).  This uptake of particles stimulates cells to release pro-
inflammatory cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), 
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prostaglandin E2 (PGE2), and IL-1β (156-160).  These cytokines, especially IL-1β, have 
been implicated in mediating osteoclast activation and/or bone resorption (123-125).  
 The role of the NLRP3 inflammasome in the response to titanium (Ti) wear-
particles has not previously been characterized.  We hypothesized that Ti particles 
activate a pro-inflammatory response in patients through activation of the 
inflammasome complex, leading to loosening and failure of the joint replacement.  To 
assess this, we first determined whether injection of Ti particles into mice led to 
neutrophil recruitment, a hallmark of acute inflammation, and whether this neutrophil 
influx was dependent on the expression of IL-1R and IL-1α/β.  To examine the 
potential for an antagonist-based therapy, we also tested whether treatment of mice with 
IL-1Ra could decrease neutrophil recruitment.  We next characterized the in vitro 
response to Ti particles, starting with determining whether Ti particles could be 
internalized in mouse macrophages.  We also examined the inflammatory cytokine 
response, including IL-1β production, induced by Ti particles in mouse and human 
macrophages.  Finally, in order to define a role for the NLRP3 inflammasome in Ti-
induced inflammation, we examined whether Ti particles could activate IL-1β secretion 
in mouse and human macrophages deficient in key components of the inflammasome 
signaling complex:  NLRP3, ASC, and Caspase-1. 
 
B.  MATERIALS AND METHODS 
Reagents: 
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 Lipopolysaccharide (LPS), Nigericin, and poly(dA:dT) sodium salt were from 
Sigma-Aldrich.  CA-074-Me, Phorbol 12-myristate 13-acetate (PMA), and GeneJuice 
transfection reagent were from EMD Chemicals.  Commercially pure titanium (Ti) 
particles (Alfa Aesar, a Johnson Matthey Company) were autoclaved in H2O, washed 
with 100% ethanol, dried under UV light in a laminar flow hood, and resuspended in 
sterile PBS for subsequent studies.  Particles were determined to have <1EU/ml of 
endotoxin using the Pyrochrome LAL endotoxin assay (Associates of Cape Cod).  
Particles (n=6708) had a median diameter of 1.86 µm with a mean diameter of 3.805 
µm (SD = 6.065 µm) as determined by confocal microscopy and (NIH) ImageJ 
software.   
 
Mice: 
 C57BL/6 (WT) and IL-1R-deficient (IL-1R KO) mice were from Jackson 
Laboratories.  CD14 KO and MD2 KO mice were a gift from D. Golenbock (UMass 
Medical School).  IL-1α/β KO mice were a gift from Y. Iwakura (University of Tokyo).  
All mouse strains, age and sex-matched with appropriate controls, were bred and 
maintained in the animal facilities at the University of Massachusetts Medical School.  
All experiments involving live animals were in accordance with guidelines set forth by 
the University of Massachusetts Medical School Department of Animal Medicine and 
the Institutional Animal Care and Use Committee. 
 
Intraperitoneal (i.p.) injections: 
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 Mice were injected i.p. with sterile PBS (500 µl), 4% thioglycolate (1 ml), or 30 
mg Ti particles (600 µl at 50 mg/ml).  For IL-1Ra studies, mice were injected 
subcutaneously with 200 µl (1 mg/kg final dose) of IL-1Ra (Anakinra™; Amgen) in 2% 
Hyaluronic Acid carrier (Calbiochem) 2 h prior to and 1h following Ti injections.  Mice 
were sacrificed by isoflurane inhalation followed by cervical dislocation.  Peritoneal 
exudate cells (PECs) were isolated 16-18 h after injections as previously described 
(127). 
 
Flow cytometric analysis: 
 To enumerate neutrophils, PECs (1x106) were incubated with anti CD16/CD32 
monoclonal antibody (clone 2.4G2; BD Biosciences) for 30 minutes to block 
FcγRIIB/III receptors and stained with Ly6G-FITC (BD Biosciences) and 7/4-Alexa647 
(AbD Serotec) for 30 minutes at 4°C.  Following staining, cells were washed with PBS 
and analyzed on a LSRII (BD Biosciences).  Neutrophil numbers in PECs were 
calculated by multiplying total cell numbers by the percentage of Ly6G+, 7/4+ cells.  
Data were acquired by DIVA (BD Biosciences) and were analyzed with FlowJo 8.8.6 
software (Tree Star Inc.).  
 
Scanning Electron Microscopy (SEM): 
 Macrophages were plated at 50-60% confluency in plastic tissue culture dishes.  
The following day, Ti particles (100 µg/ml) were added to cells for 30 minutes at 37°C.  
Cells were prepared for imaging as described in (161).  Briefly, cells were fixed in 2.5% 
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glutaraldehyde in phosphate buffer (pH 7.2).  Cells were then dehydrated though a 
graded series of ethanol followed by Critical Point Drying in CO2.  The bottoms of the 
culture dishes were mounted onto scanning stubs and coated with a 3 nm film of carbon.  
Images were acquired on a FEI Quanta 200 FEG MKII scanning electron at an 
accelerating voltage of 10kV.  Images were collected in both secondary electron 
imaging (SEI) and back-scattered electron-imaging (BSI) modes for topographic and 
atomic contrast using FEI Scandium software.  Final images, combining both the SEI 
(brown) and the BSI (blue) signals were generated using Cameo software. 
 
Spectrum Analysis: 
 The elemental composition of titanium particles was analyzed using the Oxford-
Link X-ray spectrometer on the microscope.  Energy Dispersive Spectroscopy (EDS) 
scans were collected for 200 s and the elements identified using the Oxford-Link INCA 
software package. 
 
Tissue section preparations: 
 Tissue sections were obtained from soft tissue (synovial membranes) around 
failed hip prostheses.  Sections were embedded in paraffin and stained with 
hematoxylin and eosin (H&E) for analysis.  Alternatively sections were incubated in the 
presence of xylenes, to remove paraffin, then prepared for scanning electron 
microscopy imaging using protocol described in (161).  Breifly, xylenes were removed 
by passing the tissue sections through 100% ethanol followed by Critical Point Drying 
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in CO2.  Areas in the sections that had particles of interest were removed from the tissue 
section using a small piece of double sided conductive carbon tape and placed onto a 
scanning stud.  The mounted tissue pieces were then coated with a thin film of carbon to 
make them conductive to ground.  Sections were imaged as described above.  All 
experiments involving human samples were in accordance with guidelines set forth by 
the University of Massachusetts Medical School Committee for the Protection of 
Human Subjects in Research. 
 
Cell culture: 
 Immortalized mouse macrophages from WT, NLRP3-deficient, ASC-deficient, 
and Caspase 1-deficient mice were made as previously described (104).  Briefly, bone 
marrow cells were cultured in L929-conditioned media to induce macrophage 
differentiation.  Macrophages were then infected with a J2 retrovirus expressing v-myc 
and v-raf and cultured for 3-6 months until they could grow in the absence of L929-
conditioned media.  Cells were grown in DMEM supplemented with 10% fetal calf 
serum (FCS), 1% L-glutamine, and 1% penicillin/streptomycin at 37˚C with 5% CO2.  
Cells were plated in granulocyte macrophage colony-stimulating factor (GM-CSF) (1 
ng/ml; eBioscience)-containing media for 18 h prior to stimulations.  THP-1 cells 
(ATCC) were differentiated into macrophages with 10 nM PMA for 48 h and grown in 
RPMI-1640 supplemented with 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin, 
50 µM β-Mercaptoethanol, and 10 mM HEPES at 37˚C with 10% CO2.  
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Cell stimulations: 
 For particle stimulations, mouse and human macrophages (4-5 x 105) were 
primed for 3 h with LPS (100 ng/ml) to up-regulate pro-IL-1β expression or left 
unprimed (Media), then stimulated with Ti particles at given concentrations (mg/ml), 
transfected with 400 ng of poly(dA:dT) using GeneJuice, or treated with Nigericin (5 
mM) for an additional 6 h (mouse) or 18 h (human). 
 
RNA interference: 
 Differentiated THP-1 macrophages were transfected with siGENOME 
SMARTpools (40 nM) against human NLRP3 or ASC or non-targeting (NT) siRNA #2 
using DharmaFECT 4 transfection reagent for 72 h.  Cells were then stimulated as 
described above.  All siRNA reagents were obtained from Dharmacon (Thermo Fisher 
Scientific). 
 
ELISA: 
 Cell culture supernatants were assayed for murine or human IL-1β or IL-6 with 
ELISA kits from BD Biosciences according to the manufacturer’s instructions. 
 
Statistical Analysis: 
 An unpaired, two-tailed Student’s t-test was used to determine statistical 
significance of independent experiments where two groups were compared.  When 
more than two groups were compared, a one-way ANOVA or two-way ANOVA 
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followed by Bonferroni’s correction for post test comparisons was used.  Values of p < 
0.05 were considered significant.  Statistics were performed using GraphPad (Prism 
v5.0a) software. 
 
C.  RESULTS 
Ti particles induce an IL-1-dependent neutrophil influx in vivo. 
 IL-1 plays an important role in the acute inflammatory response through 
activation and recruitment of neutrophils, a hallmark of acute inflammation (162).  
Previous studies have shown that intra-peritoneal (i.p.) injections of MSU crystals lead 
to an increase in neutrophil recruitment and that this recruitment was dependent on the 
expression of the IL-1R (127).  To examine the role of IL-1 and inflammation in the 
response to Ti particles in vivo, WT mice were injected i.p. with Ti (30 mg) and 
analyzed for neutrophil influx 16 hours later.  Mice injected with Ti exhibited a 
significant increase in neutrophils (Ly6G+7/4+) compared to injections of PBS (Figure 
3.1a).  As expected, increased neutrophil numbers were seen in mice injected with the 
positive control, thioglycolate.  To control for the possibility that LPS or endotoxin 
present on the surface of the titanium particles was responsible for the apparent immune 
response to injections, we used MD2-deficient (MD2 KO) and CD14-deficient (CD14 
KO) mice.  Both MD2 and CD14 facilitate LPS signaling through TLR4, and deficient 
mice are unresponsive to LPS (163, 164).  Ti injections were able to induce neutrophil 
influx in MD2 KO and CD14 KO mice at levels similar to WT control mice (Figure 
3.1b, c), indicating that LPS did not contribute to neutrophil recruitment by Ti. 
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Figure 3.1:  Neutrophil recruitment following Ti injections in various mouse 
strains. (a) WT (b) MD2 KO (c) CD14 KO (d) IL-1R KO and (e) IL-1α/β KO.  (f) 
Effect of IL-1Ra treatment on neutrophil recruitment.  Graphs show the mean ± s.e.m. 
from the total number of mice indicated.  Each graph represents an average at least two 
separate experiments.  To control for injection errors, separate WT controls were 
included for each deficient mouse tested.  Significance values are shown relative to (a) 
PBS, (b-e) WT, or as indicated on the graph.  P-values are shown as *** ≤ 0.0001; ** < 
0.01; * < 0.05 
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 IL-1R has been shown to be required for neutrophil recruitment following 
exposure to stimulants in mice (104, 126, 127).  To determine whether expression of IL-
1R was required for Ti-induced neutrophil influx, IL-1R-deficient (IL-1R KO) mice 
were injected with Ti and compared to WT mice.  Ti injections were unable to induce a 
neutrophil influx in IL-1R KO mice (Figure 3.1d).  Both IL-1α and IL-1β signal 
through the IL-1R.  In order to examine the role of IL-1 cytokine production on 
neutrophil recruitment, IL-1α/β KO mice were injected with Ti.  Deficient mice 
exhibited significantly lower numbers of neutrophils (Figure 3.1e), confirming a role for 
IL-1 associated signaling in the immune response to Ti wear-particles in vivo. 
 IL-1Ra, the soluble receptor antagonist of IL-1, has been used as a therapeutic 
drug to treat patients with rheumatoid arthritis to help slow or reverse progression of the 
disease.  Patients receiving the drug have exhibited a significant decrease in joint 
inflammation (130-132).  In order to examine the effects of IL-1Ra treatment on Ti-
induced inflammation, mice were injected with IL-1Ra 2 h prior and 1 h post injection 
of Ti particles.  Mice treated with IL-1Ra showed a significant decrease in neutrophil 
recruitment after injection with Ti, compared to control treated WT mice (Figure 3.1f).  
Taken together, these results indicate a critical role for IL-1 in Ti-induced neutrophil 
recruitment and introduce the possibility for a potential therapeutic treatment. 
 
Ti induces IL-1β  cytokine production in mouse and human macrophages. 
 In order to determine the molecular pathways involved in IL-1 production we 
analyzed the immune response of murine and human macrophages to titanium.  Studies 
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have shown that the immune response to Ti wear-particles involves the release of 
inflammatory cytokines, including IL-1β (157).  In order to determine whether the 
response to Ti was similar in mice, WT immortalized mouse macrophages were 
incubated with varying concentrations of purified Ti particles for 6 hours.  In order to 
specifically examine IL-1β production, macrophages were primed for 3 hours with LPS, 
to induce up-regulation of pro-IL-1β transcription, prior to Ti stimulation.  WT 
immortalized mouse macrophages responded to Ti particles in a dose-dependent manner 
with high levels of secreted IL-1β (Figure 3.2a, c).  Supernatants from macrophages that 
received an LPS prime only did not exhibit an increase in IL-1β production (Figures 3.2 
and 3.3).  As a positive control, macrophages were transfected with double-stranded 
DNA, poly-dA:dT (dA:dT).  WT macrophages produced a significant amount of IL-1β 
in response to dA:dT stimulation.  As additional controls, macrophages incubated with 
titanium particles alone produced low to un-detectable levels of IL-6, when compared to 
LPS stimulation, and IL-1β, when compared to primed cells (Figure 3.3), verifying that 
endotoxin levels associated with Ti particles did not play a role in observed cytokine 
responses.   
 A similar IL-1β response to Ti particles was seen in PMA-differentiated THP-1 
human macrophages.  Ti particles induced significantly higher levels of IL-1β secretion 
when compared to un-stimulated controls (Figure 3.2b).  As a control, human 
macrophages exhibited mature IL-1β secretion in response to Nigericin, a potassium 
ionophore known to stimulate IL-1β through induction of potassium efflux, lysosomal  
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Figure 3.2:  IL-1β  secretion following Ti stimulation.  (a, b) WT immortalized mouse 
macrophages (a) and THP-1 human macrophages (b) were primed for 3 h with LPS 
(Prime) followed by stimulation with 10 mg/ml of Ti particles (Ti 10) or left unprimed 
and unstimulated (Media).  (c, d) Dose-response curves to Ti in WT immortalized 
mouse macrophages (c) and THP-1 human macrophages (d).  Data are representative of 
at least two separate experiments performed in duplicate.  Secreted IL-1β levels are 
mean ± s.e.m.  Significance values are shown relative to Prime levels.  P-values are 
shown as *** ≤ 0.0001 
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Figure 3.3:  Titanium particles do not induce cytokine production in the absence of 
an LPS prime.  (a) IL-1β secretion in WT immortalized mouse macrophages incubated 
for 6 h with Ti particles only or Ti particles following an LPS prime for 3 h.  Dashed 
line represents LPS prime only values.  (b) IL-6 secretion following incubation with Ti 
particles only or LPS only for 6 h.  Data are representative of at least two separate 
experiments performed in duplicate.  Secreted cytokine levels are mean ± s.e.m.  
Significance values are shown relative to (a) LPS prime only or (b) no stimulant (0) 
values.  P-values are shown as *** ≤ 0.0001; * < 0.05 
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destabilization, and cathepsin B release (165).  Ti-induced IL-1β production was also 
dependent on particle concentration (Figure 3.2d).  Together, these results demonstrate 
that Ti particles induce a variety of inflammatory cytokines in mouse macrophages, and 
that both human and mouse macrophages respond to Ti particle stimulation with mature 
IL-1β secretion.   
 
Ti particles are internalized in macrophages. 
 It has been well established that part of the inflammatory response to Ti in 
patients involves the uptake of wear particles by macrophages surrounding the joint 
replacement (135, 136).  To visualize phagocytosis of Ti particles, immortalized mouse 
macrophages were incubated with Ti particles then analyzed through SEM.  Ti particles 
were highly internalized in macrophages (Figure 3.4a), with the majority of all Ti 
particles located within cells by 30 minutes.  Using confocal microscopy and Image J 
software (NIH), the overall diameter of macrophage-associated particles was 
determined.  Macrophage-associated particles had a median diameter of 1.02 µm with a 
mean diameter of 1.21 µm (S.D. = 0.79 µm) (Figure 3.4b), similar to that seen in failed 
joints (137, 138). 
 We also examined several human tissue samples from the membranes 
surrounding failed joint replacements.  Small black particles could be seen throughout 
the sections when examining H&E stained membranes (Figure 3.5a).  In order to further 
characterize the identity of these small particles, we examined the sections through 
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Figure 3.4:  Ti particles are internalized in mouse macrophages.  (a) SEM image of 
immortalized mouse macrophages incubated with Ti particles (blue) for 30 min.  
Pseudo-coloring based on electron (brown) and back scattered electron (blue) images.  
(b) Diameter of macrophage-associated particles (n = 82) as determined by confocal 
microscopy and NIH ImageJ software. 
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Figure 3.5:  Ti particles are found within patient synovial membranes.  Human 
tissue sections of membranes surrounding failed joint replacements (a) stained with 
H&E or (b) analyzed through SEM.  Arrows indicate Ti particles.  (c) Spectrum 
analysis of Ti particles within membranes.  Images are representative of four separate 
sections. 
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scanning electron microscopy.  We were able to detect small fragments of Ti particles 
(Figure 3.5b), verified through spectrum analysis (Figure 3.5c), within these 
membranes, providing direct evidence that Ti particles are present in the membranes 
surrounding failed joint replacements. 
 Following phagocytosis, particles or crystals can cause lysosomal 
destabilization, with the associated activation and release of cathepsin B into the 
cytosol.  Cathepsin B is required for optimal inflammasome activation in response to 
silica crystals, alum, and amyloid-β (104, 110).  In order to determine whether cathepsin 
is required for inflammasome activation and subsequent IL-1β production in response 
to Ti, WT immortalized mouse macrophages were treated with the cathepsin B inhibitor 
CA-074-Me.  Supernatants from cells pre-treated with CA-074-Me had significantly 
lower levels of IL-1β following Ti stimulation compared to untreated cells (Figure 
3.6a).  Treated and untreated cells produced comparable levels of the inflammasome-
independent cytokine, IL-6, in response to LPS, confirming that inhibition was 
inflammasome-specific (Figure 3.6b).  Together, these results indicate that optimal Ti-
induced IL-1β production requires cathepsin B release. 
 
Immune response to Ti requires the NLRP3 inflammasome. 
 Supernatants from immortalized macrophages generated from NLRP3- (NLRP3 
KO), ASC- (ASC KO), and Caspase-1- (CASP1 KO) deficient mice exhibited 
undetectable levels of secreted IL-β in response to Ti while IL-1β secretion from WT 
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Figure 3.6:  Response to Ti particle uptake is cathepsin B dependent.  (a) IL-1β and 
(b) IL-6 secretion following Ti stimulation (10 mg/ml) in LPS-primed (Prime) WT 
immortalized mouse macrophages treated with the cathepsin-B inhibitor, CA-074-Me.  
Data are representative of two separate experiments performed in duplicate.  Secreted 
cytokine levels are mean ± s.e.m.  Significance values are shown relative to untreated (0 
µM) samples.  P-values are shown as *** ≤ 0.0001; * < 0.05. 
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macrophages was readily detected (Figure 3.7a).  Stimulation with dA:dT induces 
mature IL-1β production in a NLRP3-independent manner (166).  As expected, NLRP3 
KO macrophages were able to respond to dA:dT similar to WT cells, while ASC KO 
and CASP1 KO macrophages were unable to respond to dA:dT.  As a control, WT and 
deficient cells were able to produce similar levels of IL-6 in response to LPS 
stimulation for 6 hours (Figure 3.7b).   
 A similar result was observed in THP-1 human macrophages.  Cells transfected 
with siRNAs against NLRP3 and ASC exhibited a significant reduction in the secretion 
of IL-1β in response to Ti particles (Figure 3.7c) compared to no siRNA or luciferase-
specific, non-targeting (NT) siRNA controls.   
 Together, these results implicate a critical role for components of the NLRP3 
inflammasome complex in the IL-1 response to Ti particles in both in vitro and in vivo. 
 
D.  DISCUSSION 
 Our results show that Ti wear-particles induce IL-1β cytokine production in 
both human and mouse macrophages leading to IL-1-associated signaling and 
subsequent neutrophil recruitment (Figure 3.8).  Although Ti is rarely used in bearing 
surfaces currently, Ti remains an important alloy used in many hip and knee 
replacements and understanding of the immune response to Ti particles is an important 
contribution to our understanding the mechanisms of implant loosening and 
periprosthetic osteolysis.  Studies have shown that among failed arthroplasties, patients 
with cemented Titanium-Aluminum-Vanadium prostheses had the highest amounts of 
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Figure 3.7:  Ti-induced IL-1β  secretion is inflammasome-dependent.  (a) IL-1β and 
(b) IL-6 secretion in WT, NLRP3 KO, ASC KO, and CASP1 KO immortalized mouse 
macrophages primed for 3 h with LPS (Prime) then stimulated with Ti (10 mg/ml) for 6 
h.  (c) IL-1β secretion following a 3 h LPS prime and 18 h Ti stimulation (10 mg/ml) in 
THP-1 human macrophages transfected with siRNA pools specific for NLRP3, ASC, or 
luciferase (NTsi).  Data are representative of at least two separate experiments 
performed in duplicate.  Secreted cytokine levels are means ± s.e.m.  Significance 
values are shown relative to (a) Prime levels or (c) NT-siRNA control levels.  P-values 
are shown as *** ≤ 0.001 
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Figure 3.8:  Diagram of Ti induced immune activation.  Ti particle internalization 
triggers the release of Cathepsin B from lysosomes, which together activate NLRP3.  
Activated NLRP3 recruits ASC through PYD domain interactions.  This complex 
triggers cleavage and recruitment of activated Caspase-1 through CARD domain 
interactions.  This inflammasome complex then cleaves pro-IL-1β into its active, 
secreted form IL-1β, which can trigger downstream IL-1 associated signaling, including 
neutrophil recruitment, through activation of the IL-1R.  This acute inflammatory 
response can be inhibited with IL-1Ra treatment. 
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IL-1β in serum, compared to patients with cemented implants comprised of other 
metals, such as Co and Cr (157), which had lower IL-1β serum levels.  Additionally, it 
has been demonstrated that patients with failed cementless total hip arthroplasties have 
significantly higher levels of TNF, IL-6 and IL-1β and increased macrophage numbers 
when osteolysis is evident (167).  Our data support these findings and suggest a 
potential mechanism for increases in IL-1β surrounding failed prostheses. 
 A role for IL-1-associated pro-inflammatory cytokine production following Ti 
rod implantation has been demonstrated in a murine intramedullary model (160), where 
a Kirshner wire was implanted into the femur of either WT or IL-1RKO mice along 
with titanium particles.  Mice deficient for the IL-1R exhibited significantly lower 
levels of pro-inflammatory cytokine production and inflammation.  Our studies support 
these observations and suggest that neutrophil recruitment may also play a role in 
inflammation.  Previous reports have also shown that implantation of 4 x 108 Ti 
particles (30 mg) onto the calvarium of mice leads to significant pro-inflammatory 
cytokine production and bone resorption after only one week (168).  Our results show 
that peritoneal injection of 30 mg of Ti particles induces acute inflammation, as seen by 
neutrophil recruitment in mice within 16 h through IL-1-associated signaling.  These 
results are consistent with other groups’ findings that neutrophils are recruited/activated 
following stimulation with particles including silica, asbestos, and MSU crystals (104, 
105, 126, 127, 169).  Our results support the hypothesis that Ti wear-particles activate a 
pro-inflammatory response in humans through IL-1-associated signaling (Figure 3.8).  
Additionally, we have shown that neutrophil recruitment following titanium injections 
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is significantly reduced in mice treated with recombinant IL-1Ra.  IL-1Ra, also known 
as Anakinra ™, has proven to be highly effective at decreasing bone erosion and joint 
space narrowing in rheumatoid arthritis patients (130-132).  Studies have shown that 
retroviral delivery of IL-1Ra was able to decrease inflammation and inflammatory 
cytokine production in a murine air pouch model of osteolysis (170).  It has also been 
shown that IL-1Ra treatment diminishes the amount of bone loss in ovariectomized rats 
and mice (171, 172), a model for post-menopausal osteoporosis.  Polymorphisms within 
the IL-1 gene cluster associated with increased IL-1Ra mRNA expression have also 
been associated with decreased susceptibility to osteolysis after total hip arthroplasty 
(173).  Along with these results, the ability of IL-1Ra to decrease neutrophilia following 
Ti injections in mice introduces the potential for antagonist-based therapies for Ti and 
other wear-particle induced inflammation. 
 We further demonstrate that Ti particles induce IL-1β secretion through 
activation of the NLRP3 inflammasome complex (Figure 3.8).  The role of the NLRP3 
inflammasome in these events is consistent with previous observations in responses to 
other implant materials, including Co and Cr metal alloys (107).  We have also 
demonstrated a role for cathepsin B in the IL-1β response to Ti particles.  This suggests 
that uptake of Ti particles induces lysosomal destabilization, releasing lysosomal 
contents and activating NLRP3.  Other particulate material, such as silica crystals, have 
been shown to induce lysosomal destabilization in this manner (104).  A role for 
cathepsin B in implant particle-induced NLRP3 activation has not previously been 
illustrated.  It is also possible that Ti particles induce NLRP3 activation through 
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production of ROS, as the IL-1β response to Co and Cr metal alloys is significantly 
diminished in cells treated with the NADPH/ROS inhibitor, DPI (107). 
 A growing number of systemic inflammatory diseases, characterized by fever, 
anemia, and elevated levels of acute-phase proteins, have been linked to abnormalities 
in NLR signaling pathways.  It is known that some patients have increased 
inflammation secondary to particulate debris and are more likely than others to develop 
osteolysis and subsequent mechanical loosening of the implant ultimately requiring 
revision joint replacement.  The mechanism associated with increased susceptibility 
remains unclear.  Defining the underlying causes of susceptibility to osteolysis will 
influence the appropriate treatment and management of particulate-induced osteolysis.  
Taken together, our results increase the understanding of how implant materials, and 
particulate material in general, interact with the host immune system and provide 
further insight into the development of treatments for Ti-particle-induced inflammation. 
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CHAPTER IV 
Examining the role of surface curvature in innate immune activation by synthetic 
microparticles 
 
A.  INTRODUCTION 
 The human immune system is poised to recognize and respond to foreign 
particulate substances, like crystals, pollen, bacteria and fungal spores.  Studies have 
indicated that following internalization, NLR protein family members are activated, 
leading to the formation of inflammasomes.  The NLRP3 inflammasome has been 
shown to recognize a variety of particulate material, including silica, asbestos, MSU 
crystals, and Co/Cr metal alloys (104-107).  The physical and chemical characteristics 
that determine the response to different particles, however, are unclear.  Pioneering 
work from Mitragotri’s group (139) and subsequent studies (139, 174-179), have clearly 
demonstrated that the shape of a polymer microparticle has dramatic effects on the 
processes of phagocytosis and immune activation.  The local curvature of the particle 
surface first encountered by the phagocyte dictates whether the actin cup necessary to 
engulf the particle can be formed (139).  While a striking correlation between geometry 
and engulfment rate was reported for “simple” particle shapes (i.e., ellipsoids, discs) 
(139) there has been no systematic study of how phagocytic rates and immune signaling 
vary with complex particle shapes.  Furthermore, the questions of how complex particle 
shapes influence these processes, as well as how particle morphology dictates the 
immune response, have not been addressed.  Our understanding of these effects remains 
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fairly limited, primarily because it has been difficult until recently to produce uniform 
microparticles with controlled surface chemistry and systematically varying shapes. 
 We have previously developed a method to create polymeric microparticles with 
complex, but well-controlled, surface morphologies that relies on emulsion processing 
of amphiphilic block copolymers such as polystyrene-block-poly(ethylene oxide) (PS-
PEO) (180).  This system provides a simple platform to tune particle morphology 
independent of other material properties.  Using this technique, formation of these 
particles is highly reproducible, with at least 90% of the particles in any batch forming 
the same morphology, and consistent from sample to sample.  The surface protrusions 
associated with particles also show a characteristic, and uniform size and density that 
depends on processing conditions. 
 Using this novel micro-capillary flow focusing technique, we aimed to define 
the role of microparticle shape in activating the immune response, which has important 
implications for engineering of delivery vehicles and implant materials.  We compared 
the ability of particles with different surface structure to be phagocytosed by mouse 
macrophages.  We also examined how particle morphology influences the level of 
immune cell activation and inflammasome activity through IL-1β cytokine release.  
Finally, we characterized the ability of particles with varying shapes to induce acute 
inflammation via neutrophil recruitment in a mouse model.  
 By systematically varying particle size, shape and surface texturing it should be 
possible to design particles with optimal immune inducing activity for their desired 
target usage.  Thus, particles for use as vaccine adjuvants could have physical properties 
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to maximize uptake and the subsequent immune response, while particles used for drug 
or siRNA delivery could have properties that maximize biodistribution but minimize 
phagocytic uptake and degradation, allowing slow release of drugs in targeted tissues. 
 
B.  MATERIALS AND METHODS 
Microparticle sample preparation:  
 Generation of solvent-in-water emulsion droplets of well-controlled sizes, flow-
focusing, and particle suspensions were conducted as previously described (181).  The 
resulting suspensions of PS-PEO microparticles were dialyzed against deionized water 
for 2 – 3 days to remove glycerol and residual chloroform.  Budding and spherical 
particles used in this study were approximately 7-8 µm in diameter. 
 
Scanning Electron Microscopy (SEM): 
 Microparticle morphologies were observed by SEM.  Particles were placed onto 
a layer of conductive carbon tape and then coated with a 4 nm layer of iridium metal.  
The images were acquired on a FEI Quanta 200 FEG MKII scanning electron at an 
accelerating voltage of 10kV.  Images were analyzed using FEI Scandium software. 
 
Cell culture: 
 Immortalized mouse macrophages from WT, NLRP3-deficient, ASC-deficient, 
and Caspase-1-deficient mice were made as previously described (104) and grown in 
DMEM supplemented with 10% FCS, 1% L-glutamine, and 1% penicillin/streptomycin 
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at 37˚C with 5% CO2. Cells were plated in media supplemented with GM-CSF (1 
ng/ml; eBioscience) for 18 h prior to stimulation. 
 
Cell Stimulations: 
 For particle stimulations, mouse macrophages (4-5 x 105) were primed for 3 h 
with LPS (100 ng/ml; Sigma) to up-regulate pro-IL-1β expression or left unprimed 
(Media), then stimulated with microparticles (budding or spherical) at given 
concentrations (µg/ml), or transfected with 400 ng of poly(dA:dT) (Sigma) using 
GeneJuice (EMD Chemicals) for an additional 6 h. 
 
Confocal Microscopy: 
 Cells were cultured on glass-bottom 35-mm tissue-culture dishes (MatTek) in 
complete medium.  Images were taken on a Leica SP2 AOBS confocal laser-scanning 
microscope with a 63x objective, using Leica Confocal Software.  Multicolor images 
were acquired by sequential scanning with only one laser active per scan to avoid cross-
excitation.  Overall brightness and contrast of images were optimized using Adobe 
Photoshop CS3. 
 
Mice injections: 
 C57BL/6 (WT) and IL-1R-deficient (IL-1R KO - 96% C57BL/6 background 
based on microsatellite analysis) were obtained from Jackson Laboratories (Bar Harbor, 
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ME).  All mouse strains, along with age and sex-matched controls, were bred and 
maintained in the animal facilities at the University of Massachusetts Medical School. 
 Mice were injected i.p. with sterile PBS (400 µl), 4% thioglycolate (1 ml), or 
450 µg of microparticles (300 µl at 1.5 mg/ml).  Mice were sacrificed by isoflurane 
inhalation followed by cervical dislocation.  PECs were isolated 6 or 16 h after 
injections as previously described (127).  All experiments involving live animals were 
in accordance with guidelines set forth by the University of Massachusetts Medical 
School Department of Animal Medicine and the Institutional Animal Care and Use 
Committee. 
 
Flow cytometric analysis: 
 To enumerate neutrophils, PECs (1x106) were incubated with anti-CD16/CD32 
monoclonal antibody (clone 2.4G2; BD Biosciences) for 30 minutes to block 
FcγRIIB/III receptors and stained with Ly6G-FITC (BD Biosciences) and 7/4-Alexa647 
(AbD Serotec) for 30 minutes at 4°C.  Following staining, cells were washed with PBS 
and analyzed on a LSRII (BD Biosciences).  Neutrophil numbers in PECs were 
calculated by multiplying total cell numbers by the percentage of Ly6G+, 7/4+ cells.  
Data were acquired by DIVA (BD Biosciences) and were analyzed with FlowJo 8.8.6 
software (Tree Star Inc.).  
 
Statistical Analysis: 
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 An unpaired, two-tailed Student’s t-test was used to determine statistical 
significance of independent experiments where two groups were compared.  When 
more than two groups were compared, a one-way ANOVA or two-way ANOVA 
followed by Bonferroni’s correction for post test comparisons was used.  Values of p < 
0.05 were considered significant.  Statistics were performed using GraphPad (Prism 
v5.0a) software. 
 
C.  RESULTS 
Budding particles are more likely to be associated with and internalized in mouse 
macrophages than spherical particles. 
 It has been well established that part of the inflammatory response to particulate 
material involves the uptake of particles by macrophages.  Recent studies have 
indicated that macrophages are more likely to internalize particles containing regions of 
high surface curvature, compared to those with low or no surface curvature (139).  
Additionally, particulates, such as alum and polystyrene, have been shown to induce 
inflammatory responses in mouse dendritic cells (182).  In order to examine this further, 
we generated PS-PEO polymer microparticles of phagocytosable size (7-8 µm) 
exhibiting regions of high surface curvature, budding particles, or low surface 
curvature, spherical particles (Figure 4.1).  To visualize phagocytosis of microparticles, 
immortalized macrophages from WT mice were incubated with budding or spherical 
microparticles incorporated with a fluorescent dye, Vibrant DiI, for 6 hours.  Using 
confocal microscopy, we found that a significantly higher percentage of budding 
 89 
 
 
 
Figure 4.1:  Images of budding and spherical microparticles.  SEM images of (A) 
budding and (B) spherical particles generated.  Scale bars = 5µm. 
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particles, greater than 85%, were associated with or internalized in macrophages when 
compared to spherical particles, approximately 20% (Figure 4.2). 
 
Budding particles associate with more cells on a per particle basis. 
 We also examined the number of macrophages associated with each particle.  
Through confocal microscopy, we found that budding particles were associated with 
more macrophages on a per particle basis (Figure 4.3b, c), whereas spherical particles 
were only associated with one macrophage per particle (Figure 4.3a, c).  This data is 
trending towards significance with a p-value of 0.0632.  These results suggest that 
particles with higher surface curvature are not only more efficiently phagocytosed by 
macrophages, but that they recruit the ‘help’ of more cells, which may play important 
roles in cellular activation and subsequent immune responses. 
 
Budding particles stimulate more IL-1β than spherical particles. 
 In order to determine if uptake efficiency played a role in the subsequent 
immune response to budding and spherical particles, we analyzed the response of 
murine macrophages to microparticles.  Immortalized macrophages from WT mice 
were primed for 3 hours with LPS to induce up-regulation of pro-IL-1β transcription, 
then incubated with budding or spherical microparticles for 6 hours to assess pro-IL-1β 
processing to mature IL-1β.  Levels of mature, secreted IL-1β were measured via 
ELISA using cell supernatants.  WT macrophages responded to both types of 
microparticles in a dose-dependent manner with significantly higher levels of secreted  
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Figure 4.2:  Budding particles are more efficiently phagocytosed by macrophages.  
Confocal microscopy images of macrophage-phagocytosed spherical (A) and budding 
(B) particles.  Lysosomes were visualized with LysoTracker Green (Molecular Probes).  
Nuclei were visualized with Hoechst 34580 (Molecular Probes).  (C) Graph shows the 
percent of and average (line) particles associated with cells per field of view.  Analysis 
was performed on seven independent fields of view per particle type.  Scale bars = 10 
µm.  P-value shown as ***<0.0001. 
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Figure 4.3:  Budding particles associate with more macrophages on a per particle 
basis.  Confocal microscopy images of macrophages associated with spherical (A) and 
budding (B) particles.  Lysosomes were visualized with LysoTracker Green (Molecular 
Probes).  Nuclei were visualized with Hoechst 34580 (Molecular Probes).  (C) Total 
and average (line) number of macrophages associated with a single particle per field of 
view.  Analysis was performed on seven independent fields of view per particle type.  
Scale bars = 10 µm. 
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IL-1β compared to priming alone at the 100 µg/ml dose for both particles as well as the 
50 µg/ml dose for budding particles (Figure 4.4a).  We also found that budding particles 
were able to induce significantly higher levels of IL-1β secretion (Figure 4.4a, black 
bars) compared to spherical particles (Figure 4.4a, white bars).  As a positive control, 
macrophages were transfected with synthetic double-stranded DNA, poly-dA:dT 
(dA:dT).  WT macrophages produced a significant amount of IL-1β in response to 
dA:dT stimulation (Figure 4.4b).  As negative controls, supernatants from macrophages 
that received media  (Media) or an LPS prime only (0) did not exhibit an increase in IL-
1β production (Figure 4.4b). 
 
Microparticle-induced IL-1β production requires the NLRP3 inflammasome. 
 Several NLR proteins have been implicated in inflammasome complex 
formation.  More specifically, it has been shown that the NLRP3 inflammasome plays a 
role in the response to particulate materials (104, 105, 127, 182).  In order to determine 
if the NLRP3 inflammasome signaling complex was also involved in the immune 
response to polystyrene particles in macrophages, immortalized macrophages generated 
from NLRP3 KO, ASC KO, and CASP1 KO deficient mice were analyzed for IL-1β 
production in response to microparticle stimulation.  Supernatants from NLRP3 KO, 
ASC KO, and CASP1 KO macrophages each exhibited undetectable levels of secreted 
IL-β in response to budding and spherical microparticles while IL-1β secretion from 
WT macrophages was readily detected (Figure 4.5a).  As expected, NLRP3 KO 
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Figure 4.4:  Particle-induced IL-1β cytokine secretion is dependent on surface 
curvature.  WT immortalized mouse macrophages were primed with LPS for 3 h (0) or 
left unprimed (Media), then stimulated for 6 h with increasing concentrations of 
budding (black bars) or spherical (white bars) particles (µg/ml) (A) or transfected with 
400 ng poly dA:dT (B).  Data are representative at least two separate experiments 
performed in duplicate.  Secreted IL-1β levels are mean ± s.e.m.  Significance values 
are shown as budding versus spherical.  P-values are shown as *** ≤ 0.0001, ** ≤ 0.01. 
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Figure 4.5:  Particle-induced IL-1β cytokine secretion requires the NLRP3 
inflammasome.  Immortalized mouse macrophages from WT, NLRP3 KO (NLRP-/-), 
ASC KO (ASC-/-), and CASP1 KO (CASP1-/-) mice were primed for 3 h with LPS 
then stimulated with 100 µg/ml spherical or budding microparticles for 6 h (A) or 
transfected with poly dA:dT (B).  Data are representative of at least two separate 
experiments performed in duplicate.  Secreted cytokine levels are mean ± s.e.m. 
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macrophages were able to respond to dA:dT similar to WT cells, while ASC KO and 
CASP1 KO macrophages were unable to respond to dA:dT (Figure 4.5b). 
 
Budding particles stimulate a more robust neutrophil response at early time 
points. 
 Previous studies have shown that i.p. injections of MSU crystals lead to an 
increase in neutrophil recruitment and that this recruitment was dependent on the 
expression of the IL-1R(127).  In order to determine whether microparticles induced a 
similar increase in neutrophil recruitment, WT mice were injected i.p. with budding or 
spherical particles (450 µg) and the peritoneal cavity was analyzed for neutrophil influx 
6 or 16 h later. Budding particles induced a more robust neutrophil response (Ly6G+, 
7/4+ cells) than spherical particles at 6 h following injection (Figure 4.6) at levels 
similar to injection with the positive control, thioglycolate (Figure 4.6a).  By 16 h post 
injection, both budding and spherical particles induced a similar increase in neutrophils 
that was significantly higher than the PBS-carrier only control (Figure 4.6b).  These 
results indicate a direct relationship between high IL-1β production in vitro and high 
neutrophil recuitment in vivo in the immune response to particulate material, 
specifically polystyrene microparticles.   
 
Microparticle-induced neutrophil recruitment involves IL-1-associated signaling. 
 The IL-1R has been shown to be required for neutrophil recruitment following  
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Figure 4.6:  Levels of neutrophil recruitment following particle injections depends 
on surface curvature.  Flow cytometric analysis on peritoneal neutrophil (Ly6G+, 7/4+ 
cells) recruitment 6 h (A) or 0, 6, and 16 h (B) after microparticle (450 µg) injections in 
WT (C57BL/6) mice.  Peritoneal neutrophil numbers were compared to PBS only (PBS 
or 0) or thioglycolate (Thio) controls.  Data are representative of at least two separate 
experiments.  Graphs show mean ± s.e.m of number of mice indicated.  Significance 
values are shown as budding versus spherical (A) or timed particle versus time 0 
injections (B).  P-values are shown as *** ≤ 0.0001; ** < 0.01; * < 0.05 
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exposure to stimulants in mice (104, 126, 127).  To determine whether expression of IL-
1R was required for microparticle-induced neutrophil influx, IL-1R KO mice were 
injected with budding or spherical particles for 16 h and compared to WT mice.  As 
expected, microparticle injections were unable to induce a neutrophil influx in IL-1R 
KO mice (Figure 4.7).  These results suggest that surface curvature plays a critical role 
in both the in vitro and in vivo response to polymeric microparticles, where high surface 
curvature leads to increased internalization, increased IL-1β cytokine production, and a 
more robust neutrophil response. 
 
D.  DISCUSSION 
 This study illustrates a significant role for surface curvature in polymer 
microparticle-induced stimulation, both in vitro and in vivo.  We have shown that large 
(7-8 µm) polymer particles are efficiently phagocytosed by macrophages.  Interestingly, 
greater than 80% of budding particles were found associated with macrophages 
compared to 20% of spherical particles under the same conditions.  We also noted 
higher concentrations of lysosomes surrounding the engulfed budding particles (Figure 
4.2b) suggesting that the budding particles trigger a stronger cellular response.  A recent 
study indicated that macrophages are more likely to internalize particles if they contain 
regions of high surface curvature compared to regions of low or no surface curvature 
(139).  Therefore, it is possible that the budding particles are more likely to be 
phagocytosed because they contain higher local surface curvature compared to spherical 
particles. 
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Figure 4.7:  Particle-induced neutrophil recruitment requires IL-1-associated 
signaling.  Flow cytometric analysis on peritoneal neutrophil (Ly6G+, 7/4+ cells) 
recruitment 16 h after microparticle (450 µg) injections in WT or IL-1RKO mice.  Data 
are representative of two separate experiments.  Graphs show mean ± s.e.m of the 
number of mice indicated. 
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 We have also shown that budding particles induce a significantly more robust 
innate immune response in immortalized mouse macrophages.  Furthermore, this 
response is dependent on components of the NLRP3 inflammasome signaling pathway, 
similar to that seen with other particulate stimuli (104, 105, 127).  Recent work has 
shown that polymer particles measuring 1 µm in diameter stimulate higher amounts of 
IL-1β than larger particles of the same composition (182).  Based on this, our results 
suggest that budding particles induce higher levels of IL-1β secretion than spherical 
particles because the macrophage senses the “buds” as smaller particles. 
 Budding particles induce a higher neutrophil response at early time points (6 h) 
after peritoneal injections than spherical particles.  Conversely, both types of particles 
are able to induce similar levels of neutrophil recruitment by 16 h after injection.  These 
results suggest that budding particles are able to induce immune responses faster in 
vivo, but that this increased induction is not sustained and spherical particles will 
ultimately stimulate similar induction levels.  This may be a result of the fact that 
budding particles are more likely to be phagocytosed by macrophages and induce higher 
levels of cytokines, when compared to spherical particles. 
 We, and others, have demonstrated a critical role for IL-1-associated signaling 
in neutrophil responses following injections of particulate stimuli (104, 105, 127).  Here 
we show that IL-1R KO mice exhibit a diminished neutrophil response following 
microparticle injections, further implicating IL-1 signaling in the innate immune 
response to budding and spherical polymer microparticles.   
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 Overall, this data has broad implications for the future development of vaccine 
adjuvants and therapeutic delivery agents, as variation in surface curvature will 
modulate the resultant immune response.  We suggest that particles with low surface 
curvature would be ideal for use as delivery vehicles, as they exhibit a low level of 
uptake and induce a slow immune response, and thus, may exhibit a broader 
biodistribution, ideal for delivery of therapeutic agents.  On the other hand, we suggest 
that particles with high surface curvature would be ideal for the use as vaccine 
adjuvants, as they are more efficiently phagocytosed in cells and induce a more robust 
immune response. 
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CHAPTER V 
A.  SUMMARY 
 Endocytotic and phagocytotic pathways are important for many cellular 
functions including cell maintenance, cell survival, receptor recycling, receptor 
signaling, antigen presentation, and protection from extracellular pathogens.  Both 
pathways involve receptor binding at the surface of the cell followed by internalization 
and movement through portions of the endosomal pathway.   
 In this dissertation, the differences between antibody-mediated and ligand-
mediated internalization of cell surface proteins were examined.  Results indicate that 
antibodies directed to cell surface proteins will divert internalization and localization to 
compartments associated with the degradative endosomal pathway.  This has broad 
applicability for antibody therapeutics and antibody-based delivery vehicles.  Work 
described here also examined the immune response to titanium wear-particles.  Results 
show that phagocytosed titanium particles generated from joint replacements activate 
the NLRP3 inflammasome, leading to pro-inflammatory cytokine production and 
neutrophil recruitment.  Further understanding the basis for joint replacement failure 
may aid in the development of specific treatments for affected patients.  Finally, the role 
of surface curvature in the immune response to polymeric microparticles was examined.  
Results indicate that surface curvature plays a pronounced role, independent of 
chemical composition and surface ligand recognition, in the immune response to 
phagocytosed microparticles.  This data may help guide the development of future 
particulate-based delivery vehicles and adjuvants.  Overall, work on the above projects 
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demonstrates how basic cell functions, such as endocytosis and phagocytosis (and their 
downstream effects) can be utilized to develop therapeutics against a variety of 
diseases, including cancers, viral infections, periprosthetic osteolysis, and more. 
 In the first chapter, the ability of antibodies to mediate internalization of cell 
surface-expressed target proteins through receptor-mediated endocytosis was examined.  
Although antibodies have most commonly been utilized to target specific cells for Fc-
mediated killing, in recent years, antibodies have also been utilized to mediate 
internalization and degradation of target proteins and to deliver a variety of therapeutic 
agents to a preferred subset of cells.  Some of these approaches involve targeting cell 
surface receptor proteins expressed by tumors or viral proteins selectively expressed on 
infected cells.  This defined targeting of antibodies has been shown to mediate 
internalization of β-amyloid from the surface of neuronal cells (80, 82-84), to deliver 
anti-tumor drugs using tumor-specific cell markers (81, 87, 88), and to deliver antiviral 
siRNAs exclusively to infected cells (79, 92). 
 It has been suggested that in order for an antibody therapeutic to be efficacious 
at either mediating down-regulation of the surface proteins, or to deliver drugs or 
siRNAs into the cytoplasm of cells, it must internalize through a degradation pathway, 
including localization with low pH compartments, such as late endosomes and 
lysosomes, where the drugs would be released from the antibody or the target protein 
will be degraded (78-80).  Through examination of a variety of antibody-mediated 
delivery studies, it was clear that most antibody-protein conjugates were delivered to a 
degradative compartment.  Due to the broad-range of cell surface proteins that have 
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been successfully utilized for antibody-based internalization or delivery, we 
hypothesized that one may not have to choose therapeutic targets based on their natural 
localization to degradative endosomes following internalization, but that perhaps, 
antibody binding would divert internalization of cell surface proteins, to some extent, 
through this pathway. 
 The transferrin receptor is expressed on most cell types, including cells in the 
brain and is highly expressed in tumor cells (183).  As such, groups have studied the 
ability to use the TfR as a therapeutic target.  Some groups have looked at conjugating 
drugs or DNA to Tf to mediate delivery into cells, while other groups have examined 
conjugating drugs or DNA to antibodies specific for the TfR (183).  We examined 
whether an antibody specific for the TfR could divert internalization of the protein into 
a degradation pathway.  When bound to its natural ligand, transferrin, the receptor 
progressively co-localizes with clathrin, followed by the early endosomal proteins 
Rab5a, Rab4, and the recycling endosomal marker Rab11.  If binding of an antibody to 
the TfR could divert localization to include late endosomes, this would suggest that 
antibody binding alone could guide internalization through a degradation internalization 
pathway. 
 Using an antibody specific for the exofacial, or extracellular, domain of the TfR, 
αCD71, the internalization of the TfR/αCD71 complex based on its localization to 
endosomal proteins was examined.  Although localization to recycling-associated 
endosomes remained intact following antibody binding, the TfR/αCD71 complex was 
also diverted to include localization with the late endosomal marker, Rab9, in 
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agreement with our hypothesis.  This indicates that antibody binding can induce a shift 
in endosomal localization to degradation endosomes, even if the ‘natural-ligand’ 
mediated pathway does not include these compartments. 
 Taking advantage of the ability of antibodies and antibody-conjugates to bind to 
and subsequently internalize target proteins expressed on the surface of a particular 
subset of cells could also be utilized for the treatment of a variety of viral infections, by 
specifically targeting infected cells.  As such, the antibody-mediated internalization 
pattern of rabies G expressed on the surface of mouse neuroblastoma cells, to mimic an 
infected cell state (154), was characterized.  Rabies virus infections occur in over 100 
countries and territories and are fatal once symptoms develop (153).  To prevent 
development of the disease, treatment of exposed individuals includes administration of 
the rabies vaccine and human rabies immune globulin, which helps to neutralize the 
virus. 
 There are several ways that rabies G-specific antibodies have been shown to 
mediate inhibition of the virus.  Neutralizing antibodies can bind to the virion-expressed 
glycoprotein to either block infection of target cells or to inhibit escape of the virus 
from endosomal compartments following entry (184), an important step in viral 
uncoating.  Antibodies can also bind to rabies G expressed on the surface of infected 
cells to inhibit cell-to-cell spread (185).  Given that other virus-specific antibody 
therapeutics have been used for either down regulation of viral glycoproteins or to 
introduce virus specific siRNAs to cells (79, 92), the ability of an antibody binding to 
rabies G to induce internalization and localization of the protein to degradative 
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endosomal compartments was examined.  Using a humanized monoclonal antibody 
specific for rabies G, ARG1, we found that the ARG1/rabies G complex exhibited an 
internalization pathway similar to that of the antibody-bound TfR, including 
localization with endosomal compartments associated with the degradation pathway, 
including Rab5a, Rab9, and lysosomes. 
 Although these studies suggest that antibodies bound to cell surface proteins can 
mediate localization to degradative compartments within a cell, it would be of great 
interest to examine how these antibodies are guiding this internalization pathway.  
Studies have shown that internalization of plasma membrane receptors through a 
degradation pathway involves ubiquitination.  The EGF receptor, for example, is 
ubiquitinated by the ubiquitin ligase c-Cbl following ligand binding, which induces 
internalization and sorting of the receptor to multivesicular bodies (186-188).  It is 
possible that when an antibody binds to a cell surface protein/receptor like the TfR or 
rabies G, a signal for ubiquitination is induced. 
This potential mechanism does not address why fluorescent antibody bound to 
the TfR is localized to compartments associated with both the recycling pathway and 
degradative pathway.  One simple explanation might be that the observed localization to 
degradative endosomes is simply a visualization of antibody no longer complexed to the 
TfR.  However, preliminary data using fluorescent TfR-expressing cells has shown that 
fluorescent antibody remains complexed with the receptor throughout the time course 
examined in the above studies (data not shown).  Therefore, it is unlikely that 
localization to late endosomes is a visualization of antibody alone.  Further 
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characterization of the signaling mechanisms involved following binding of the TfR to 
antibody, including the cytosolic proteins involved, would help increase the general 
understanding of how different ligands bound to TfR, in this case antibody versus Tf, 
can mediate differential localization to certain endosomal compartments. 
 In the next two chapters, the downstream signaling events involved following 
phagocytosis of particulate material in macrophages were examined.  As previously 
mentioned, phagocytosis can occur through binding of opsonized particles to 
complement-receptors and Fc-receptors, or through binding of particles to PRRs, 
including TLRs, mannose receptors, and scavenger receptors, expressed on the surface 
of immune cells, including macrophages.  Binding to these receptors stimulates 
intracellular signaling events associated with the immune response as well as eventual 
internalization of the particles.  Following phagocytosis, particulate material such as 
silica, asbestos, MSU crystals, and cobalt/chromium metal alloys activate NLRP3 (104-
107), a NOD-like receptor protein located in the cytosol of macrophages.  Activation of 
the NLRP3 inflammasome pathway results in the cleavage of pro-IL-1β into its mature 
secreted form, IL-1β.  In this dissertation, uptake, inflammasome activation, and 
subsequent immune responses to two clinically relevant particulate materials, titanium 
and polymeric microparticles, were examined. 
 Osteolysis, or degradation, of bone following total joint replacements is a major 
clinical problem.  Examination of the areas surrounding failed implants has indicated an 
increase in wear particles, including titanium particles, as well as an increase in the 
bone-resorption-inducing cytokine, IL-1β.  Here, we’ve shown that titanium particles 
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injected into the peritoneum of mice induced neutrophil recruitment that was dependent 
on the expression of the IL-1 receptor (IL-1R) and IL-1α/β.  Moreover, treatment with 
the IL-1R antagonist (IL-1Ra) diminished this response.  In vitro, titanium-induced IL-
1β secretion from macrophages was dependent on the expression of components of the 
NLRP3 inflammasome.  Together, these results suggest that titanium wear-particle 
induced inflammation and subsequent joint replacement failure may be due to activation 
of the NLRP3 inflammasome, leading to increased IL-1β secretion and IL-1 associated 
signaling. 
 Our data, and the work of others, indicate that the NLRP3 inflammasome 
signaling pathway is critical in the host response to implant materials, including 
titanium, cobalt, and chromium (107).  It is known that certain patients have increased 
inflammation secondary to particulate debris and are more likely than others to develop 
osteolysis and subsequent mechanical loosening of the implant ultimately requiring 
revision surgery.  Until recently, the mechanism associated with increased (or 
decreased) susceptibility has been unclear.  A growing number of systemic 
inflammatory diseases, characterized by fever, anemia, and elevated levels of acute-
phase proteins, have been linked to abnormalities in NLR signaling pathways, as 
exemplified by the 'cryopyrinopathies', also termed 'the CIAS1-associated periodic 
syndromes' (reviewed in (115)).  These cryopyrinopathies constitute a subfamily of the 
hereditary periodic fever syndromes, and the clinical presentation includes unexplained 
episodes of fever and severe localized inflammation, including arthritis and joint 
destruction.  One study has shown that patients containing a polymorphism in the IL-
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1Ra gene exhibit decreased susceptibility to osteolysis following a cemented, 
polyethylene-on-metal total hip arthroplasty (173).  This data suggests that patients who 
are more susceptible to joint inflammation may express polymorphisms in 
inflammasome-related genes that predispose to this condition, analogous to 
cryopyrinopathies like Muckle-Wells syndrome which is characterized by spontaneous 
secretion of active IL-1β (114). 
 Defining the underlying causes of osteolysis following joint replacements will 
influence the appropriate treatment and management of particulate-induced osteolysis 
and possibly identify those patients at high risk for this condition pre-operatively before 
the primary total joint replacement.  For example, these patients at increased risk may 
benefit from IL-1R antagonists as prophylaxis or treatment at the time of joint 
replacement.  In an ideal situation, different polymorphisms will be associated with the 
response to different implant materials.  This would allow surgeons to specifically 
select the implant material that would cause the least amount of damage long-term.  A 
more realistic outcome, however, is that all susceptible patients exhibit a variety of 
polymorphisms associated with NLR- or IL-1-associated genes.  At the very least, 
patients identified as ‘high-risk’ can be watched more closely for potential 
inflammation and, if it occurs, can be treated appropriately. 
 Polymeric microparticles have been investigated as platforms for drug delivery, 
adjuvants, and as imaging contrast agents.  Due to the increased use of these types of 
particles in a variety of clinical settings, it is important to understand how physical 
characteristics, including size and shape, of these particles play a role in uptake 
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efficiency and subsequent immune cell activation.  Certain types of particles are 
phagocytosed by macrophages more efficiently than others.  Different particles can also 
induce significant inflammation or may be relatively well tolerated.  The physical and 
chemical characteristics that determine these responses are unclear.   
 Our results indicate that particles with high surface curvature (budding particles) 
are phagocytosed by macrophages at a higher frequency than particles with low surface 
curvature (spherical particles).  The efficiency with which a particle is phagocytosed 
can play a major role in efficacy of either a delivery vehicle or a vaccine adjuvant.  For 
example, if a particle is to be used as a vaccine adjuvant, it is important that efficient 
phagocytosis takes place, allowing antigens to be presented in MHC complexes on 
antigen presenting cells.  However, if a particle is designed for delivery to a particular 
subset of non-immune cells, rapid phagocytosis by macrophages can be problematic, 
since it would lead to accumulation in the undesired cell type, decreasing delivery to 
target cells.  This data suggests that particles that exhibit characteristics similar to 
budding particles would be optimal as vaccine adjuvants, as they are more likely to be 
phagocytosed by macrophages.  Conversely, particles destined for delivery vehicles 
should exhibit characteristics similar to spherical particles, which exhibit lower levels of 
macrophage uptake. 
 Remarkably, budding particles also induced stronger IL-1β secretion than 
spherical particles, through activation of the NLRP3 inflammasome-signaling complex.  
Additionally, compared to spherical particles, budding particles induced more rapid IL-
1-dependent neutrophil recruitment in vivo to the injection site.  Recent findings by 
 111 
Sharp et al. has suggested that particles within the range of 0.5-1 µm in diameter induce 
the highest amount of IL-1β in dendritic cells following phagocytosis (182).  Although 
the overall diameter of the budding and spherical particles ranged between 7-8 µm, the 
‘buds’ on the budding particles averaged a relative diameter of about 1-2 µm.  It is 
possible that the budding particles induce a more robust inflammatory response than 
spherical particles because the macrophage sensed the ‘buds’ as smaller particles.  It 
would be of interest to directly compare budding particles to small, spherical particles in 
the range of 0.5-2 µm in diameter to see if uptake efficiency is equivalent and if IL-1β 
secretion and neutrophil recruitment are at comparable levels. 
Adjuvants enhance the ability of vaccines to activate and direct adaptive 
immune responses.  Until recently, the mechanism of how adjuvants drive innate and 
adaptive immune responses was unclear.  The commonly used particulate adjuvant, 
Alum, has now been shown to induce IL-1β cytokine production in a NLRP3 
inflammasome-dependent manner (189, 190).  Studies have also shown that the 
production of pro-inflammatory cytokines, including IL-1, is essential to induce fully 
active T cell responses and promote protective immunity in mice challenged with a 
specific antigen (191, 192).  When combined with IL-2, IL-1β induces optimal 
proliferation of naïve CD4+ T cells in response to antigen (191).  This data suggests that 
particulate adjuvants, like Alum, may exhibit their effect in part through activation of 
the NLRP3 inflammasome to produce active IL-1β, which can, in turn, induce a more 
robust CD4+ T cell response.  Since budding and spherical particles induce different 
levels of IL-1β secretion and early neutrophil recruitment, it would be of interest to 
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examine if these characteristics play a role in the level of CD4+ T cell activation.  More 
specifically, it would be of interest to determine whether budding particles would 
induce a more robust CD4+ T cell response than spherical particles. 
 Overall, findings in this dissertation have potential applications to not only guide 
the development of future targeting vehicles for delivery of vaccines, drugs, proteins, 
and siRNA therapeutics but also to develop more specific treatments for patients 
suffering from particulate-induced inflammation and bone loss. 
 113 
CHAPTER VI 
 
References 
 
1. Mellman, I. 1996. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 
12:575-625. 
2. Mayor, S., and R.E. Pagano. 2007. Pathways of clathrin-independent 
endocytosis. Nat Rev Mol Cell Biol 8:603-612. 
3. Kirkham, M., A. Fujita, R. Chadda, S.J. Nixon, T.V. Kurzchalia, D.K. Sharma, 
R.E. Pagano, J.F. Hancock, S. Mayor, and R.G. Parton. 2005. Ultrastructural 
identification of uncoated caveolin-independent early endocytic vehicles. J Cell 
Biol 168:465-476. 
4. Kirkham, M., and R.G. Parton. 2005. Clathrin-independent endocytosis: new 
insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 
1746:349-363. 
5. Sabharanjak, S., P. Sharma, R.G. Parton, and S. Mayor. 2002. GPI-anchored 
proteins are delivered to recycling endosomes via a distinct cdc42-regulated, 
clathrin-independent pinocytic pathway. Dev Cell 2:411-423. 
6. Mukherjee, S., R.N. Ghosh, and F.R. Maxfield. 1997. Endocytosis. Physiol Rev 
77:759-803. 
7. Aderem, A., and D.M. Underhill. 1999. Mechanisms of phagocytosis in 
macrophages. Annu Rev Immunol 17:593-623. 
8. Rabinovitch, M. 1995. Professional and non-professional phagocytes: an 
introduction. Trends Cell Biol 5:85-87. 
 114 
9. Tjelle, T.E., T. Lovdal, and T. Berg. 2000. Phagosome dynamics and function. 
Bioessays 22:255-263. 
10. Fratti, R.A., J.M. Backer, J. Gruenberg, S. Corvera, and V. Deretic. 2001. Role 
of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis 
and mycobacterial phagosome maturation arrest. J Cell Biol 154:631-644. 
11. Underhill, D.M., and A. Ozinsky. 2002. Phagocytosis of microbes: complexity 
in action. Annu Rev Immunol 20:825-852. 
12. Janeway, C. 2005. Immunobiology : the immune system in health and disease 
(pp. 55-75). Garland Science, New York.  
13. Ravetch, J.V., and S. Bolland. 2001. IgG Fc receptors. Annu Rev Immunol 
19:275-290. 
14. Ghazizadeh, S., J.B. Bolen, and H.B. Fleit. 1994. Physical and functional 
association of Src-related protein tyrosine kinases with Fc gamma RII in 
monocytic THP-1 cells. J Biol Chem 269:8878-8884. 
15. Cox, D., P. Chang, T. Kurosaki, and S. Greenberg. 1996. Syk tyrosine kinase is 
required for immunoreceptor tyrosine activation motif-dependent actin 
assembly. J Biol Chem 271:16597-16602. 
16. Majeed, M., E. Caveggion, C.A. Lowell, and G. Berton. 2001. Role of Src 
kinases and Syk in Fcgamma receptor-mediated phagocytosis and phagosome-
lysosome fusion. J Leukoc Biol 70:801-811. 
17. Mukhopadhyay, S., and S. Gordon. 2004. The role of scavenger receptors in 
pathogen recognition and innate immunity. Immunobiology 209:39-49. 
 115 
18. Palecanda, A., J. Paulauskis, E. Al-Mutairi, A. Imrich, G. Qin, H. Suzuki, T. 
Kodama, K. Tryggvason, H. Koziel, and L. Kobzik. 1999. Role of the scavenger 
receptor MARCO in alveolar macrophage binding of unopsonized 
environmental particles. J Exp Med 189:1497-1506. 
19. Krieger, M., and J. Herz. 1994. Structures and functions of multiligand 
lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related 
protein (LRP). Annu Rev Biochem 63:601-637. 
20. Pearson, A.M. 1996. Scavenger receptors in innate immunity. Curr Opin 
Immunol 8:20-28. 
21. Elomaa, O., M. Kangas, C. Sahlberg, J. Tuukkanen, R. Sormunen, A. Liakka, I. 
Thesleff, G. Kraal, and K. Tryggvason. 1995. Cloning of a novel bacteria-
binding receptor structurally related to scavenger receptors and expressed in a 
subset of macrophages. Cell 80:603-609. 
22. Hamilton, R.F., Jr., S.A. Thakur, J.K. Mayfair, and A. Holian. 2006. MARCO 
mediates silica uptake and toxicity in alveolar macrophages from C57BL/6 
mice. J Biol Chem 281:34218-34226. 
23. Kanno, S., A. Furuyama, and S. Hirano. 2007. A murine scavenger receptor 
MARCO recognizes polystyrene nanoparticles. Toxicol Sci 97:398-406. 
24. Ungewickell, E., and D. Branton. 1981. Assembly units of clathrin coats. Nature 
289:420-422. 
25. Smith, C.J., and B.M. Pearse. 1999. Clathrin: anatomy of a coat protein. Trends 
Cell Biol 9:335-338. 
 116 
26. Rappoport, J.Z., S. Kemal, A. Benmerah, and S.M. Simon. 2006. Dynamics of 
clathrin and adaptor proteins during endocytosis. Am J Physiol Cell Physiol 
291:C1072-1081. 
27. Rappoport, J.Z., A. Benmerah, and S.M. Simon. 2005. Analysis of the AP-2 
adaptor complex and cargo during clathrin-mediated endocytosis. Traffic 6:539-
547. 
28. Hinshaw, J.E. 2000. Dynamin and its role in membrane fission. Annu Rev Cell 
Dev Biol 16:483-519. 
29. Ungewickell, E., H. Ungewickell, S.E. Holstein, R. Lindner, K. Prasad, W. 
Barouch, B. Martin, L.E. Greene, and E. Eisenberg. 1995. Role of auxilin in 
uncoating clathrin-coated vesicles. Nature 378:632-635. 
30. Umeda, A., A. Meyerholz, and E. Ungewickell. 2000. Identification of the 
universal cofactor (auxilin 2) in clathrin coat dissociation. Eur J Cell Biol 
79:336-342. 
31. Lamaze, C., L.M. Fujimoto, H.L. Yin, and S.L. Schmid. 1997. The actin 
cytoskeleton is required for receptor-mediated endocytosis in mammalian cells. 
J Biol Chem 272:20332-20335. 
32. Yarar, D., C.M. Waterman-Storer, and S.L. Schmid. 2005. A dynamic actin 
cytoskeleton functions at multiple stages of clathrin-mediated endocytosis. Mol 
Biol Cell 16:964-975. 
33. Jeng, R.L., and M.D. Welch. 2001. Cytoskeleton: actin and endocytosis--no 
longer the weakest link. Curr Biol 11:R691-694. 
 117 
34. Roth, M.G. 2007. Integrating actin assembly and endocytosis. Dev Cell 13:3-4. 
35. Sandvig, K., and B. van Deurs. 1990. Selective modulation of the endocytic 
uptake of ricin and fluid phase markers without alteration in transferrin 
endocytosis. J Biol Chem 265:6382-6388. 
36. Gottlieb, T.A., I.E. Ivanov, M. Adesnik, and D.D. Sabatini. 1993. Actin 
microfilaments play a critical role in endocytosis at the apical but not the 
basolateral surface of polarized epithelial cells. J Cell Biol 120:695-710. 
37. Dunn, K.W., T.E. McGraw, and F.R. Maxfield. 1989. Iterative fractionation of 
recycling receptors from lysosomally destined ligands in an early sorting 
endosome. J Cell Biol 109:3303-3314. 
38. Kornfeld, S., and I. Mellman. 1989. The biogenesis of lysosomes. Annu Rev Cell 
Biol 5:483-525. 
39. Zerial, M., and H. McBride. 2001. Rab proteins as membrane organizers. Nat 
Rev Mol Cell Biol 2:107-117. 
40. Somsel Rodman, J., and A. Wandinger-Ness. 2000. Rab GTPases coordinate 
endocytosis. J Cell Sci 113 Pt 2:183-192. 
41. Gruenberg, J. 2001. The endocytic pathway: a mosaic of domains. Nat Rev Mol 
Cell Biol 2:721-730. 
42. Geuze, H.J., J.W. Slot, G.J. Strous, H.F. Lodish, and A.L. Schwartz. 1983. 
Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label 
immunoelectron microscopy during receptor-mediated endocytosis. Cell 32:277-
287. 
 118 
43. Marsh, M., G. Griffiths, G.E. Dean, I. Mellman, and A. Helenius. 1986. Three-
dimensional structure of endosomes in BHK-21 cells. Proc Natl Acad Sci U S A 
83:2899-2903. 
44. Gruenberg, J., G. Griffiths, and K.E. Howell. 1989. Characterization of the early 
endosome and putative endocytic carrier vesicles in vivo and with an assay of 
vesicle fusion in vitro. J Cell Biol 108:1301-1316. 
45. Maxfield, F.R., and T.E. McGraw. 2004. Endocytic recycling. Nat Rev Mol Cell 
Biol 5:121-132. 
46. Schmid, S., R. Fuchs, M. Kielian, A. Helenius, and I. Mellman. 1989. 
Acidification of endosome subpopulations in wild-type Chinese hamster ovary 
cells and temperature-sensitive acidification-defective mutants. J Cell Biol 
108:1291-1300. 
47. Sipe, D.M., and R.F. Murphy. 1987. High-resolution kinetics of transferrin 
acidification in BALB/c 3T3 cells: exposure to pH 6 followed by temperature-
sensitive alkalinization during recycling. Proc Natl Acad Sci U S A 84:7119-
7123. 
48. Yamashiro, D.J., and F.R. Maxfield. 1987. Acidification of morphologically 
distinct endosomes in mutant and wild-type Chinese hamster ovary cells. J Cell 
Biol 105:2723-2733. 
49. Schmid, S.L., R. Fuchs, P. Male, and I. Mellman. 1988. Two distinct 
subpopulations of endosomes involved in membrane recycling and transport to 
lysosomes. Cell 52:73-83. 
 119 
50. Bucci, C., R.G. Parton, I.H. Mather, H. Stunnenberg, K. Simons, B. Hoflack, 
and M. Zerial. 1992. The small GTPase rab5 functions as a regulatory factor in 
the early endocytic pathway. Cell 70:715-728. 
51. Gorvel, J.P., P. Chavrier, M. Zerial, and J. Gruenberg. 1991. rab5 controls early 
endosome fusion in vitro. Cell 64:915-925. 
52. Zerial, M. 1993. Regulation of endocytosis by the small GTP-ase rab5. 
Cytotechnology 11 Suppl 1:S47-49. 
53. Nielsen, E., F. Severin, J.M. Backer, A.A. Hyman, and M. Zerial. 1999. Rab5 
regulates motility of early endosomes on microtubules. Nat Cell Biol 1:376-382. 
54. Van Der Sluijs, P., M. Hull, A. Zahraoui, A. Tavitian, B. Goud, and I. Mellman. 
1991. The small GTP-binding protein rab4 is associated with early endosomes. 
Proc Natl Acad Sci U S A 88:6313-6317. 
55. Mohrmann, K., L. Gerez, V. Oorschot, J. Klumperman, and P. van der Sluijs. 
2002. Rab4 function in membrane recycling from early endosomes depends on a 
membrane to cytoplasm cycle. J Biol Chem 277:32029-32035. 
56. van der Sluijs, P., M. Hull, P. Webster, P. Male, B. Goud, and I. Mellman. 1992. 
The small GTP-binding protein rab4 controls an early sorting event on the 
endocytic pathway. Cell 70:729-740. 
57. Vitale, G., V. Rybin, S. Christoforidis, P. Thornqvist, M. McCaffrey, H. 
Stenmark, and M. Zerial. 1998. Distinct Rab-binding domains mediate the 
interaction of Rabaptin-5 with GTP-bound Rab4 and Rab5. EMBO J 17:1941-
1951. 
 120 
58. Sonnichsen, B., S. De Renzis, E. Nielsen, J. Rietdorf, and M. Zerial. 2000. 
Distinct membrane domains on endosomes in the recycling pathway visualized 
by multicolor imaging of Rab4, Rab5, and Rab11. J Cell Biol 149:901-914. 
59. Ren, M., G. Xu, J. Zeng, C. De Lemos-Chiarandini, M. Adesnik, and D.D. 
Sabatini. 1998. Hydrolysis of GTP on rab11 is required for the direct delivery of 
transferrin from the pericentriolar recycling compartment to the cell surface but 
not from sorting endosomes. Proc Natl Acad Sci U S A 95:6187-6192. 
60. Schmidt, M.R., and V. Haucke. 2007. Recycling endosomes in neuronal 
membrane traffic. Biol Cell 99:333-342. 
61. Ullrich, O., S. Reinsch, S. Urbe, M. Zerial, and R.G. Parton. 1996. Rab11 
regulates recycling through the pericentriolar recycling endosome. J Cell Biol 
135:913-924. 
62. Wilcke, M., L. Johannes, T. Galli, V. Mayau, B. Goud, and J. Salamero. 2000. 
Rab11 regulates the compartmentalization of early endosomes required for 
efficient transport from early endosomes to the trans-golgi network. J Cell Biol 
151:1207-1220. 
63. Clague, M.J., S. Urbe, F. Aniento, and J. Gruenberg. 1994. Vacuolar ATPase 
activity is required for endosomal carrier vesicle formation. J Biol Chem 269:21-
24. 
64. Hopkins, C.R., A. Gibson, M. Shipman, and K. Miller. 1990. Movement of 
internalized ligand-receptor complexes along a continuous endosomal reticulum. 
Nature 346:335-339. 
 121 
65. Geuze, H.J., W. Stoorvogel, G.J. Strous, J.W. Slot, J.E. Bleekemolen, and I. 
Mellman. 1988. Sorting of mannose 6-phosphate receptors and lysosomal 
membrane proteins in endocytic vesicles. J Cell Biol 107:2491-2501. 
66. Piper, R.C., and J.P. Luzio. 2001. Late endosomes: sorting and partitioning in 
multivesicular bodies. Traffic 2:612-621. 
67. Ganley, I.G., K. Carroll, L. Bittova, and S. Pfeffer. 2004. Rab9 GTPase 
regulates late endosome size and requires effector interaction for its stability. 
Mol Biol Cell 15:5420-5430. 
68. Barbero, P., L. Bittova, and S.R. Pfeffer. 2002. Visualization of Rab9-mediated 
vesicle transport from endosomes to the trans-Golgi in living cells. J Cell Biol 
156:511-518. 
69. Riederer, M.A., T. Soldati, A.D. Shapiro, J. Lin, and S.R. Pfeffer. 1994. 
Lysosome biogenesis requires Rab9 function and receptor recycling from 
endosomes to the trans-Golgi network. J Cell Biol 125:573-582. 
70. Lombardi, D., T. Soldati, M.A. Riederer, Y. Goda, M. Zerial, and S.R. Pfeffer. 
1993. Rab9 functions in transport between late endosomes and the trans Golgi 
network. EMBO J 12:677-682. 
71. Schneider, C., R. Sutherland, R. Newman, and M. Greaves. 1982. Structural 
features of the cell surface receptor for transferrin that is recognized by the 
monoclonal antibody OKT9. J Biol Chem 257:8516-8522. 
 122 
72. Dautry-Varsat, A., A. Ciechanover, and H.F. Lodish. 1983. pH and the recycling 
of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A 
80:2258-2262. 
73. Huebers, H.A., and C.A. Finch. 1987. The physiology of transferrin and 
transferrin receptors. Physiol Rev 67:520-582. 
74. Ward, J.H., J.P. Kushner, and J. Kaplan. 1982. Regulation of HeLa cell 
transferrin receptors. J Biol Chem 257:10317-10323. 
75. Aisen, P., and I. Listowsky. 1980. Iron transport and storage proteins. Annu Rev 
Biochem 49:357-393. 
76. Sainte-Marie, J., V. Lafont, E.I. Pecheur, J. Favero, J.R. Philippot, and A. 
Bienvenue. 1997. Transferrin receptor functions as a signal-transduction 
molecule for its own recycling via increases in the internal Ca2+ concentration. 
Eur J Biochem 250:689-697. 
77. Ohno, H., J. Stewart, M.C. Fournier, H. Bosshart, I. Rhee, S. Miyatake, T. Saito, 
A. Gallusser, T. Kirchhausen, and J.S. Bonifacino. 1995. Interaction of tyrosine-
based sorting signals with clathrin-associated proteins. Science 269:1872-1875. 
78. Perera, R.M., R. Zoncu, T.G. Johns, M. Pypaert, F.T. Lee, I. Mellman, L.J. Old, 
D.K. Toomre, and A.M. Scott. 2007. Internalization, intracellular trafficking, 
and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth 
factor receptor antibody. Neoplasia 9:1099-1110. 
79. Song, E., P. Zhu, S.K. Lee, D. Chowdhury, S. Kussman, D.M. Dykxhoorn, Y. 
Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, and J. Lieberman. 
 123 
2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-
surface receptors. Nat Biotechnol 23:709-717. 
80. Tampellini, D., J. Magrane, R.H. Takahashi, F. Li, M.T. Lin, C.G. Almeida, and 
G.K. Gouras. 2007. Internalized antibodies to the Abeta domain of APP reduce 
neuronal Abeta and protect against synaptic alterations. J Biol Chem 282:18895-
18906. 
81. Polson, A.G., S.F. Yu, K. Elkins, B. Zheng, S. Clark, G.S. Ingle, D.S. Slaga, L. 
Giere, C. Du, C. Tan, J.A. Hongo, A. Gogineni, M.J. Cole, R. Vandlen, J.P. 
Stephan, J. Young, W. Chang, S.J. Scales, S. Ross, D. Eaton, and A. Ebens. 
2007. Antibody-drug conjugates targeted to CD79 for the treatment of non-
Hodgkin lymphoma. Blood 110:616-623. 
82. Solomon, B., and D. Frenkel. 2010. Immunotherapy for Alzheimer's disease. 
Neuropharmacology In press:1-7. 
83. Hock, C., U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-
Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, M.A. Wollmer, D. 
Umbricht, D.J. de Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos, 
and R.M. Nitsch. 2003. Antibodies against beta-amyloid slow cognitive decline 
in Alzheimer's disease. Neuron 38:547-554. 
84. Masliah, E., L. Hansen, A. Adame, L. Crews, F. Bard, C. Lee, P. Seubert, D. 
Games, L. Kirby, and D. Schenk. 2005. Abeta vaccination effects on plaque 
pathology in the absence of encephalitis in Alzheimer disease. Neurology 
64:129-131. 
 124 
85. Peer, D., P. Zhu, C.V. Carman, J. Lieberman, and M. Shimaoka. 2007. Selective 
gene silencing in activated leukocytes by targeting siRNAs to the integrin 
lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 104:4095-
4100. 
86. Li, X., P. Stuckert, I. Bosch, J.D. Marks, and W.A. Marasco. 2001. Single-chain 
antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. 
Cancer Gene Ther 8:555-565. 
87. Kamizuru, H., H. Kimura, T. Yasukawa, Y. Tabata, Y. Honda, and Y. Ogura. 
2001. Monoclonal antibody-mediated drug targeting to choroidal 
neovascularization in the rat. Invest Ophthalmol Vis Sci 42:2664-2672. 
88. Kaspar, M., E. Trachsel, and D. Neri. 2007. The antibody-mediated targeted 
delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits 
tumor growth and metastasis. Cancer Res 67:4940-4948. 
89. Sarmiento, R.E., R.G. Tirado, L.E. Valverde, and B. Gomez-Garcia. 2007. 
Kinetics of antibody-induced modulation of respiratory syncytial virus antigens 
in a human epithelial cell line. Virol J 4:68. 
90. Chesebro, B., K. Wehrly, D. Doig, and J. Nishio. 1979. Antibody-induced 
modulation of Friend virus cell surface antigens decreases virus production by 
persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad 
Sci U S A 76:5784-5788. 
91. Dowdle, W.R., J.C. Downie, and W.G. Laver. 1974. Inhibition of virus release 
by antibodies to surface antigens of influenza viruses. J Virol 13:269-275. 
 125 
92. Wen, W.H., J.Y. Liu, W.J. Qin, J. Zhao, T. Wang, L.T. Jia, Y.L. Meng, H. Gao, 
C.F. Xue, B.Q. Jin, L.B. Yao, S.Y. Chen, and A.G. Yang. 2007. Targeted 
inhibition of HBV gene expression by single-chain antibody mediated small 
interfering RNA delivery. Hepatology 46:84-94. 
93. Witko-Sarsat, V., P. Rieu, B. Descamps-Latscha, P. Lesavre, and L. Halbwachs-
Mecarelli. 2000. Neutrophils: molecules, functions and pathophysiological 
aspects. Lab Invest 80:617-653. 
94. Dale, D.C., L. Boxer, and W.C. Liles. 2008. The phagocytes: neutrophils and 
monocytes. Blood 112:935-945. 
95. Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat Rev Immunol 
4:499-511. 
96. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int 
Immunol 17:1-14. 
97. Kawai, T., and S. Akira. 2007. TLR signaling. Semin Immunol 19:24-32. 
98. Martinon, F., and J. Tschopp. 2005. NLRs join TLRs as innate sensors of 
pathogens. Trends Immunol 26:447-454. 
99. Mariathasan, S., K. Newton, D.M. Monack, D. Vucic, D.M. French, W.P. Lee, 
M. Roose-Girma, S. Erickson, and V.M. Dixit. 2004. Differential activation of 
the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213-218. 
100. Martinon, F., A. Mayor, and J. Tschopp. 2009. The inflammasomes: guardians 
of the body. Annu Rev Immunol 27:229-265. 
 126 
101. Tschopp, J., F. Martinon, and K. Burns. 2003. NALPs: a novel protein family 
involved in inflammation. Nat Rev Mol Cell Biol 4:95-104. 
102. Fitzgerald, K.A. 2010. NLR-containing inflammasomes: central mediators of 
host defense and inflammation. Eur J Immunol 40:595-598. 
103. Franchi, L., T. Eigenbrod, R. Munoz-Planillo, and G. Nunez. 2009. The 
inflammasome: a caspase-1-activation platform that regulates immune responses 
and disease pathogenesis. Nat Immunol 10:241-247. 
104. Hornung, V., F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, 
K.A. Fitzgerald, and E. Latz. 2008. Silica crystals and aluminum salts activate 
the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 
9:847-856. 
105. Martinon, F., V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp. 2006. Gout-
associated uric acid crystals activate the NALP3 inflammasome. Nature 
440:237-241. 
106. Dostert, C., V. Petrilli, R. Van Bruggen, C. Steele, B.T. Mossman, and J. 
Tschopp. 2008. Innate immune activation through Nalp3 inflammasome sensing 
of asbestos and silica. Science 320:674-677. 
107. Caicedo, M.S., R. Desai, K. McAllister, A. Reddy, J.J. Jacobs, and N.J. Hallab. 
2008. Soluble and particulate Co-Cr-Mo alloy implant metals activate the 
inflammasome danger signaling pathway in human macrophages: A novel 
mechanism for implant debris reactivity. J Orthop Res 27:847-854. 
 127 
108. Martinon, F. 2010. Signaling by ROS drives inflammasome activation. Eur J 
Immunol 40:616-619. 
109. Zhou, R., A. Tardivel, B. Thorens, I. Choi, and J. Tschopp. 2010. Thioredoxin-
interacting protein links oxidative stress to inflammasome activation. Nat 
Immunol 11:136-140. 
110. Halle, A., V. Hornung, G.C. Petzold, C.R. Stewart, B.G. Monks, T. Reinheckel, 
K.A. Fitzgerald, E. Latz, K.J. Moore, and D.T. Golenbock. 2008. The NALP3 
inflammasome is involved in the innate immune response to amyloid-beta. Nat 
Immunol 9:857-865. 
111. Hornung, V., and E. Latz. 2010. Critical functions of priming and lysosomal 
damage for NLRP3 activation. Eur J Immunol 40:620-623. 
112. Masumoto, J., S. Taniguchi, K. Ayukawa, H. Sarvotham, T. Kishino, N. 
Niikawa, E. Hidaka, T. Katsuyama, T. Higuchi, and J. Sagara. 1999. ASC, a 
novel 22-kDa protein, aggregates during apoptosis of human promyelocytic 
leukemia HL-60 cells. J Biol Chem 274:33835-33838. 
113. Mariathasan, S., and D.M. Monack. 2007. Inflammasome adaptors and sensors: 
intracellular regulators of infection and inflammation. Nat Rev Immunol 7:31-
40. 
114. Agostini, L., F. Martinon, K. Burns, M.F. McDermott, P.N. Hawkins, and J. 
Tschopp. 2004. NALP3 forms an IL-1beta-processing inflammasome with 
increased activity in Muckle-Wells autoinflammatory disorder. Immunity 
20:319-325. 
 128 
115. Neven, B., A.M. Prieur, and P. Quartier dit Maire. 2008. Cryopyrinopathies: 
update on pathogenesis and treatment. Nat Clin Pract Rheumatol 4:481-489. 
116. Dinarello, C.A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-
2147. 
117. Dinarello, C.A. 2010. IL-1: discoveries, controversies and future directions. Eur 
J Immunol 40:599-606. 
118. Werman, A., R. Werman-Venkert, R. White, J.K. Lee, B. Werman, Y. Krelin, E. 
Voronov, C.A. Dinarello, and R.N. Apte. 2004. The precursor form of IL-1alpha 
is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U 
S A 101:2434-2439. 
119. Bauernfeind, F.G., G. Horvath, A. Stutz, E.S. Alnemri, K. MacDonald, D. 
Speert, T. Fernandes-Alnemri, J. Wu, B.G. Monks, K.A. Fitzgerald, V. 
Hornung, and E. Latz. 2009. Cutting edge: NF-kappaB activating pattern 
recognition and cytokine receptors license NLRP3 inflammasome activation by 
regulating NLRP3 expression. J Immunol 183:787-791. 
120. Hise, A.G., J. Tomalka, S. Ganesan, K. Patel, B.A. Hall, G.D. Brown, and K.A. 
Fitzgerald. 2009. An essential role for the NLRP3 inflammasome in host 
defense against the human fungal pathogen Candida albicans. Cell Host Microbe 
5:487-497. 
121. Franchi, L., R. Munoz-Planillo, T. Reimer, T. Eigenbrod, and G. Nunez. 2010. 
Inflammasomes as microbial sensors. Eur J Immunol 40:611-615. 
 129 
122. Daun, J.M., and M.J. Fenton. 2000. Interleukin-1/Toll receptor family members: 
receptor structure and signal transduction pathways. J Interferon Cytokine Res 
20:843-855. 
123. Stashenko, P., F.E. Dewhirst, W.J. Peros, R.L. Kent, and J.M. Ago. 1987. 
Synergistic interactions between interleukin 1, tumor necrosis factor, and 
lymphotoxin in bone resorption. J Immunol 138:1464-1468. 
124. Assuma, R., T. Oates, D. Cochran, S. Amar, and D.T. Graves. 1998. IL-1 and 
TNF antagonists inhibit the inflammatory response and bone loss in 
experimental periodontitis. J Immunol 160:403-409. 
125. Thomson, B.M., G.R. Mundy, and T.J. Chambers. 1987. Tumor necrosis factors 
alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. 
J Immunol 138:775-779. 
126. Chen, C.J., H. Kono, D. Golenbock, G. Reed, S. Akira, and K.L. Rock. 2007. 
Identification of a key pathway required for the sterile inflammatory response 
triggered by dying cells. Nat Med 13:851-856. 
127. Chen, C.J., Y. Shi, A. Hearn, K. Fitzgerald, D. Golenbock, G. Reed, S. Akira, 
and K.L. Rock. 2006. MyD88-dependent IL-1 receptor signaling is essential for 
gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 
116:2262-2271. 
128. Ogilvie, A.C., C.E. Hack, J. Wagstaff, G.J. van Mierlo, A.J. Erenberg, L.L. 
Thomsen, K. Hoekman, and E.M. Rankin. 1996. IL-1 beta does not cause 
 130 
neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release 
when used in patients with cancer. J Immunol 156:389-394. 
129. Evans, R.J., J. Bray, J.D. Childs, G.P. Vigers, B.J. Brandhuber, J.J. Skalicky, 
R.C. Thompson, and S.P. Eisenberg. 1995. Mapping receptor binding sites in 
interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed 
mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta. J 
Biol Chem 270:11477-11483. 
130. Abramson, S.B., and A. Amin. 2002. Blocking the effects of IL-1 in rheumatoid 
arthritis protects bone and cartilage. Rheumatology (Oxford) 41:972-980. 
131. Bresnihan, B., J.M. Alvaro-Gracia, M. Cobby, M. Doherty, Z. Domljan, P. 
Emery, G. Nuki, K. Pavelka, R. Rau, B. Rozman, I. Watt, B. Williams, R. 
Aitchison, D. McCabe, and P. Musikic. 1998. Treatment of rheumatoid arthritis 
with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 
41:2196-2204. 
132. Jiang, Y., H.K. Genant, I. Watt, M. Cobby, B. Bresnihan, R. Aitchison, and D. 
McCabe. 2000. A multicenter, double-blind, dose-ranging, randomized, 
placebo-controlled study of recombinant human interleukin-1 receptor 
antagonist in patients with rheumatoid arthritis: radiologic progression and 
correlation of Genant and Larsen scores. Arthritis Rheum 43:1001-1009. 
133. Dinarello, C.A., and R.C. Thompson. 1991. Blocking IL-1: interleukin 1 
receptor antagonist in vivo and in vitro. Immunol Today 12:404-410. 
 131 
134. Saeed, S., and P.A. Revell. 2001. Production and distribution of interleukin 15 
and its receptors (IL-15Ralpha and IL-R2beta) in the implant interface tissues 
obtained during revision of failed total joint replacement. Int J Exp Pathol 
82:201-209. 
135. Revell, P.A. 2008. The combined role of wear particles, macrophages and 
lymphocytes in the loosening of total joint prostheses. J R Soc Interface 5:1263-
1278. 
136. Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total 
joint replacement. Biomaterials 26:1271-1286. 
137. Lee, J.M., E.A. Salvati, F. Betts, E.F. DiCarlo, S.B. Doty, and P.G. Bullough. 
1992. Size of metallic and polyethylene debris particles in failed cemented total 
hip replacements. J Bone Joint Surg Br 74:380-384. 
138. Margevicius, K.J., T.W. Bauer, J.T. McMahon, S.A. Brown, and K. Merritt. 
1994. Isolation and characterization of debris in membranes around total joint 
prostheses. J Bone Joint Surg Am 76:1664-1675. 
139. Champion, J.A., and S. Mitragotri. 2006. Role of target geometry in 
phagocytosis. Proc Natl Acad Sci U S A 103:4930-4934. 
140. Favoreel, H.W., T.C. Mettenleiter, and H.J. Nauwynck. 2004. Copatching and 
lipid raft association of different viral glycoproteins expressed on the surfaces of 
pseudorabies virus-infected cells. J Virol 78:5279-5287. 
141. Van de Walle, G.R., H.W. Favoreel, H.J. Nauwynck, P. Van Oostveldt, and 
M.B. Pensaert. 2001. Involvement of cellular cytoskeleton components in 
 132 
antibody-induced internalization of viral glycoproteins in pseudorabies virus-
infected monocytes. Virology 288:129-138. 
142. Favoreel, H.W., H.J. Nauwynck, H.M. Halewyck, P. Van Oostveldt, T.C. 
Mettenleiter, and M.B. Pensaert. 1999. Antibody-induced endocytosis of viral 
glycoproteins and major histocompatibility complex class I on pseudorabies 
virus-infected monocytes. J Gen Virol 80 ( Pt 5):1283-1291. 
143. Sloan, S.E., C. Hanlon, W. Weldon, M. Niezgoda, J. Blanton, J. Self, K.J. 
Rowley, R.B. Mandell, G.J. Babcock, W.D. Thomas, Jr., C.E. Rupprecht, and 
D.M. Ambrosino. 2007. Identification and characterization of a human 
monoclonal antibody that potently neutralizes a broad panel of rabies virus 
isolates. Vaccine 25:2800-2810. 
144. Bellve, K.D., D. Leonard, C. Standley, L.M. Lifshitz, R.A. Tuft, A. Hayakawa, 
S. Corvera, and K.E. Fogarty. 2006. Plasma membrane domains specialized for 
clathrin-mediated endocytosis in primary cells. J Biol Chem 281:16139-16146. 
145. Leonard, D., A. Hayakawa, D. Lawe, D. Lambright, K.D. Bellve, C. Standley, 
L.M. Lifshitz, K.E. Fogarty, and S. Corvera. 2008. Sorting of EGF and 
transferrin at the plasma membrane and by cargo-specific signaling to EEA1-
enriched endosomes. J Cell Sci 121:3445-3458. 
146. Green, E.G., E. Ramm, N.M. Riley, D.J. Spiro, J.R. Goldenring, and M. 
Wessling-Resnick. 1997. Rab11 is associated with transferrin-containing 
recycling compartments in K562 cells. Biochem Biophys Res Commun 239:612-
616. 
 133 
147. Harding, C., J. Heuser, and P. Stahl. 1983. Receptor-mediated endocytosis of 
transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell 
Biol 97:329-339. 
148. Axelrod, D. 2003. Total internal reflection fluorescence microscopy in cell 
biology. Methods Enzymol 361:1-33. 
149. Axelrod, D. 2001. Total internal reflection fluorescence microscopy in cell 
biology. Traffic 2:764-774. 
150. Li, G., and P.D. Stahl. 1993. Structure-function relationship of the small GTPase 
rab5. J Biol Chem 268:24475-24480. 
151. Trachsel, E., F. Bootz, M. Silacci, M. Kaspar, H. Kosmehl, and D. Neri. 2007. 
Antibody-mediated delivery of IL-10 inhibits the progression of established 
collagen-induced arthritis. Arthritis Res Ther 9:R9. 
152. Marecos, E., R. Weissleder, and A. Bogdanov, Jr. 1998. Antibody-mediated 
versus nontargeted delivery in a human small cell lung carcinoma model. 
Bioconjug Chem 9:184-191. 
153. WHO. 2007. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 
82:425-435. 
154. Wiktor, T.J., and H. Koprowski. 1978. Monoclonal antibodies against rabies 
virus produced by somatic cell hybridization: detection of antigenic variants. 
Proc Natl Acad Sci U S A 75:3938-3942. 
155. Jacobs, J.J., K.A. Roebuck, M. Archibeck, N.J. Hallab, and T.T. Glant. 2001. 
Osteolysis: basic science. Clin Orthop Relat Res 393:71-77. 
 134 
156. Stea, S., M. Visentin, D. Granchi, G. Ciapetti, M.E. Donati, A. Sudanese, C. 
Zanotti, and A. Toni. 2000. Cytokines and osteolysis around total hip prostheses. 
Cytokine 12:1575-1579. 
157. Granchi, D., E. Verri, G. Ciapetti, S. Stea, L. Savarino, A. Sudanese, M. Mieti, 
R. Rotini, D. Dallari, G. Zinghi, and L. Montanaro. 1998. Bone-resorbing 
cytokines in serum of patients with aseptic loosening of hip prostheses. J Bone 
Joint Surg Br 80:912-917. 
158. Rader, C.P., T. Sterner, F. Jakob, N. Schutze, and J. Eulert. 1999. Cytokine 
response of human macrophage-like cells after contact with polyethylene and 
pure titanium particles. J Arthroplasty 14:840-848. 
159. Boynton, E.L., J. Waddell, E. Meek, R.S. Labow, V. Edwards, and J.P. Santerre. 
2000. The effect of polyethylene particle chemistry on human monocyte-
macrophage function in vitro. J Biomed Mater Res 52:239-245. 
160. Epstein, N.J., B.A. Warme, J. Spanogle, T. Ma, B. Bragg, R.L. Smith, and S.B. 
Goodman. 2005. Interleukin-1 modulates periprosthetic tissue formation in an 
intramedullary model of particle-induced inflammation. J Orthop Res 23:501-
510. 
161. Hayat, M.A. 1978. Introduction to biological scanning electron microscopy. 
University Park Press, Baltimore. 323 p. pp. 
162. Oliveira, S.H., C. Canetti, R.A. Ribeiro, and F.Q. Cunha. 2008. Neutrophil 
migration induced by IL-1beta depends upon LTB4 released by macrophages 
 135 
and upon TNF-alpha and IL-1beta released by mast cells. Inflammation 31:36-
46. 
163. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. 
Kitamura, A. Kosugi, M. Kimoto, and K. Miyake. 2002. Essential role of MD-2 
in LPS responsiveness and TLR4 distribution. Nat Immunol 3:667-672. 
164. Wright, S.D., R.A. Ramos, P.S. Tobias, R.J. Ulevitch, and J.C. Mathison. 1990. 
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding 
protein. Science 249:1431-1433. 
165. Hentze, H., X.Y. Lin, M.S. Choi, and A.G. Porter. 2003. Critical role for 
cathepsin B in mediating caspase-1-dependent interleukin-18 maturation and 
caspase-1-independent necrosis triggered by the microbial toxin nigericin. Cell 
Death Differ 10:956-968. 
166. Muruve, D.A., V. Petrilli, A.K. Zaiss, L.R. White, S.A. Clark, P.J. Ross, R.J. 
Parks, and J. Tschopp. 2008. The inflammasome recognizes cytosolic microbial 
and host DNA and triggers an innate immune response. Nature 452:103-107. 
167. Chiba, J., H.E. Rubash, K.J. Kim, and Y. Iwaki. 1994. The characterization of 
cytokines in the interface tissue obtained from failed cementless total hip 
arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res 
300:304-312. 
168. Schwarz, E.M., A.P. Lu, J.J. Goater, E.B. Benz, G. Kollias, R.N. Rosier, J.E. 
Puzas, and R.J. O'Keefe. 2000. Tumor necrosis factor-alpha/nuclear 
 136 
transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 
18:472-480. 
169. Schumacher, H.R., and C.A. Agudelo. 1972. Intravascular degranulation of 
neutrophils: an important factor in inflammation? Science 175:1139-1140. 
170. Sud, S., S.Y. Yang, C.H. Evans, P.D. Robbins, and P.H. Wooley. 2001. Effects 
of cytokine gene therapy on particulate-induced inflammation in the murine air 
pouch. Inflammation 25:361-372. 
171. Kimble, R.B., J.L. Vannice, D.C. Bloedow, R.C. Thompson, W. Hopfer, V.T. 
Kung, C. Brownfield, and R. Pacifici. 1994. Interleukin-1 receptor antagonist 
decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 
93:1959-1967. 
172. Baltzer, A.W., J.D. Whalen, P. Wooley, C. Latterman, L.M. Truchan, P.D. 
Robbins, and C.H. Evans. 2001. Gene therapy for osteoporosis: evaluation in a 
murine ovariectomy model. Gene Ther 8:1770-1776. 
173. Gordon, A., E. Kiss-Toth, I. Stockley, R. Eastell, and J.M. Wilkinson. 2008. 
Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes 
affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum 
58:3157-3165. 
174. Champion, J.A., and S. Mitragotri. 2009. Shape induced inhibition of 
phagocytosis of polymer particles. Pharm Res 26:244-249. 
175. Hubbell, J.A., S.N. Thomas, and M.A. Swartz. 2009. Materials engineering for 
immunomodulation. Nature 462:449-460. 
 137 
176. van Zon, J.S., G. Tzircotis, E. Caron, and M. Howard. 2009. A mechanical 
bottleneck explains the variation in cup growth during Fc gamma R 
phagocytosis. Molecular Systems Biology 5:298. 
177. Canelas, D.A., K.P. Herlihy, and J.M. DeSimone. 2009. Top-down particle 
fabrication: control of size and shape for diagnostic imaging and drug delivery. 
Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 1:391-
404. 
178. Decuzzi, P., B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, and M. 
Ferrari. 2010. Size and shape effects in the biodistribution of intravascularly 
injected particles. Journal of Controlled Release 141:320-327. 
179. Doshi, N., and S. Mitragotri. 2010. Macrophages Recognize Size and Shape of 
Their Targets. PLoS ONE 5:e10051. 
180. Zhu, J., and R.C. Hayward. 2008. Hierarchically structured microparticles 
formed by interfacial instabilities of emulsion droplets containing amphiphilic 
block copolymers. Angewandte Chemie International Edition 47:2113-2116. 
181. Zhu, J., and R.C. Hayward. 2008. Spontaneous generation of amphiphilic block 
copolymer micelles with multiple morphologies through interfacial Instabilities. 
J Am Chem Soc 130:7496-7502. 
182. Sharp, F.A., D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, M. Singh, 
D.T. O'Hagan, V. Petrilli, J. Tschopp, L.A. O'Neill, and E.C. Lavelle. 2009. 
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 
inflammasome. Proc Natl Acad Sci U S A 106:870-875. 
 138 
183. Qian, Z.M., H. Li, H. Sun, and K. Ho. 2002. Targeted drug delivery via the 
transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561-587. 
184. Dietzschold, B., M. Tollis, M. Lafon, W.H. Wunner, and H. Koprowski. 1987. 
Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal 
antibodies. Virology 161:29-36. 
185. Lodmell, D.L., and L.C. Ewalt. 1987. Immune sera and antiglycoprotein 
monoclonal antibodies inhibit in vitro cell-to-cell spread of pathogenic rabies 
viruses. J Virol 61:3314-3318. 
186. de Melker, A.A., G. van der Horst, and J. Borst. 2004. c-Cbl directs EGF 
receptors into an endocytic pathway that involves the ubiquitin-interacting motif 
of Eps15. J Cell Sci 117:5001-5012. 
187. de Melker, A.A., G. van der Horst, J. Calafat, H. Jansen, and J. Borst. 2001. c-
Cbl ubiquitinates the EGF receptor at the plasma membrane and remains 
receptor associated throughout the endocytic route. J Cell Sci 114:2167-2178. 
188. Levkowitz, G., H. Waterman, E. Zamir, Z. Kam, S. Oved, W.Y. Langdon, L. 
Beguinot, B. Geiger, and Y. Yarden. 1998. c-Cbl/Sli-1 regulates endocytic 
sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 
12:3663-3674. 
189. Li, H., S.B. Willingham, J.P. Ting, and F. Re. 2008. Cutting edge: 
inflammasome activation by alum and alum's adjuvant effect are mediated by 
NLRP3. J Immunol 181:17-21. 
 139 
190. Eisenbarth, S.C., O.R. Colegio, W. O'Connor, F.S. Sutterwala, and R.A. Flavell. 
2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory 
properties of aluminium adjuvants. Nature 453:1122-1126. 
191. Curtsinger, J.M., C.S. Schmidt, A. Mondino, D.C. Lins, R.M. Kedl, M.K. 
Jenkins, and M.F. Mescher. 1999. Inflammatory cytokines provide a third signal 
for activation of naive CD4+ and CD8+ T cells. J Immunol 162:3256-3262. 
192. Pape, K.A., A. Khoruts, A. Mondino, and M.K. Jenkins. 1997. Inflammatory 
cytokines enhance the in vivo clonal expansion and differentiation of antigen-
activated CD4+ T cells. J Immunol 159:591-598. 
 
 
